[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 254
1. Huang Y, Moreau A, Dupuis J, Streubel B, Petit B, Le Gouill S, Martin-Garcia N, Copie-Bergman C, Gaillard F, Qubaja M, Fabiani B, Roncador G, Haioun C, Delfau-Larue MH, Marafioti T, Chott A, Gaulard P: Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol; 2009 May;33(5):682-90
HAL archives ouvertes. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas.
  • Rare cases of peripheral T-cell lymphomas with follicular growth pattern (PTCL-F) have been recently reported, and their association with t(5;9)(q33;q22) involving ITK and SYK has been suggested.
  • However, the clinicopathologic aspects of PTCL-F are poorly described and the normal cell counterpart of this subgroup of lymphoma is still unknown.
  • Patients with clinical data available had multiple lymphadenopathies (25/28, 89%), stage III to IV diseases (17/26, 65%), B symptoms (7/27, 26%), and skin lesions (6/23, 26%).
  • Three patients with sequential biopsies disclosed clinical and histopathologic features of angioimmunoblastic T-cell lymphoma at initial presentation.
  • Our results show that this rare form of PTCL-F (1) has an immunophenotype indicative of derivation from TFH cells, (2) is associated with t(5;9) in a proportion of cases, and (3) shows some overlapping features with angioimmunoblastic T-cell lymphoma, raising the question of a possible relationship.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, Follicular / pathology. Lymphoma, T-Cell, Peripheral / pathology. T-Lymphocytes, Helper-Inducer / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Antigens, CD4 / analysis. Antigens, Differentiation, T-Lymphocyte / analysis. Apoptosis Regulatory Proteins / analysis. Biopsy. Chemokine CXCL13 / analysis. Chromosomes, Human, Pair 5. Chromosomes, Human, Pair 9. DNA-Binding Proteins / analysis. Europe. Gene Expression Regulation, Neoplastic. Gene Rearrangement, T-Lymphocyte. Genotype. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Inducible T-Cell Co-Stimulator Protein. Middle Aged. Neoplasm Staging. Neprilysin / analysis. Phenotype. Programmed Cell Death 1 Receptor. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295409.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD4; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / BCL6 protein, human; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / DNA-Binding Proteins; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC4838638
  •  go-up   go-down


2. Chen W, Kesler MV, Karandikar NJ, McKenna RW, Kroft SH: Flow cytometric features of angioimmunoblastic T-cell lymphoma. Cytometry B Clin Cytom; 2006 May;70(3):142-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric features of angioimmunoblastic T-cell lymphoma.
  • BACKGROUND: The immunophenotypic features of angioimmunoblastic T-cell lymphoma (AILT) have not been well described.
  • METHODS: We retrospectively reviewed our institutional experience with the flow cytometric features of 16 cases of AILT.
  • CD10 was expressed by the neoplastic populations in 11 of 14 cases at diagnosis; in 3 of these 11 only a subpopulation of the neoplastic cells was CD10(+).
  • CONCLUSIONS: These results indicate the potential utility of flow cytometry in the diagnosis and follow-up of AILT.
  • [MeSH-major] Flow Cytometry / methods. Immunoblastic Lymphadenopathy / pathology. Immunophenotyping / methods. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Antigens, CD3 / analysis. Antigens, CD45 / analysis. Antigens, CD7 / analysis. Bone Marrow / pathology. Female. Follow-Up Studies. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neprilysin / analysis. Receptors, Complement 3d / analysis. Retrospective Studies. T-Lymphocytes / chemistry. T-Lymphocytes / metabolism. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 International Society for Analytical Cytology.
  • (PMID = 16572417.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD7; 0 / Receptors, Complement 3d; EC 3.1.3.48 / Antigens, CD45; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


3. Choi JH, Oh YH, Park IK: A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma. Cancer Res Treat; 2010 Jun;42(2):115-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma.
  • Pure red cell aplasia is a bone marrow failure characterized by a progressive normocytic anemia and reticulocytopenia without leucopenia and thrombocytopenia.
  • It is associated with various hematologic diseases.
  • However, pure red cell aplasia with angioimmunoblastic T cell lymphoma has rarely been reported.
  • Here we describe a 43-year-old woman with pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma.
  • A CT scan of the abdomen revealed marked hepatosplenomegaly and small multiple lymphadenopathies.
  • A bone marrow biopsy revealed focal infiltration of abnormal lymphoid cells and absence of red cell precursors.
  • Splenic biopsy was compatible with angioimmunoblastic T-cell lymphoma.
  • Ultimately, diagnosis of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma was made.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Haematol. 1996;96(2):68-72 [8701703.001]
  • [Cites] Am J Hematol. 1994 Jun;46(2):72-8 [8172198.001]
  • [Cites] J R Soc Med. 1983 Oct;76(10):894-5 [6631867.001]
  • [Cites] Am J Hematol. 1999 Dec;62(4):259-60 [10589086.001]
  • [Cites] Biomed Pharmacother. 2003 Oct;57(8):326-32 [14568226.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Haematologica. 1982 Nov-Dec;67(6):919-25 [6819197.001]
  • (PMID = 20622966.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2901080
  • [Keywords] NOTNLM ; Lymphoma / Pure / Red-cell aplasia / T-cell
  •  go-up   go-down


Advertisement
4. Oka K, Nagayama R, Yatabe Y, Iijima S, Mori N: Angioimmunoblastic T-cell lymphoma with autoimmune thrombocytopenia: a report of two cases. Pathol Res Pract; 2010 Apr 15;206(4):270-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with autoimmune thrombocytopenia: a report of two cases.
  • We report two patients, a 68-year-old man (Case 1) and a 66-year-old man (Case 2), with polyclonal gammopathy, lymphadenopathy, thrombocytopenia, and high platelet-associated IgG (PAIgG) level.
  • We initially diagnosed them as having angioimmunoblastic lymphadenopathy with dysproteinemia (AILD).
  • From confirmation of clear cells by careful observation and detection of rearrangement bands of T cell receptors by Southern blot hybridization analysis, we finally concluded that their diagnoses were compatible with angioimmunoblastic T-cell lymphoma (AILT).
  • AILT with autoimmune thrombocytopenia (AIT) is very rare, and all the reported cases were Japanese ones.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / pathology. Purpura, Thrombocytopenic, Idiopathic / pathology
  • [MeSH-minor] Aged. Blotting, Southern. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19442454.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A: Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol; 2006 Aug;19(8):1101-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified.
  • The germinal center T-helper cell has been proposed as the cell of origin for angioimmunoblastic T-cell lymphoma.
  • Our recent report of expression of CXCL13, a chemokine critical for germinal center formation and one of the most highly upregulated genes in the germinal center T-helper cell subset, in the majority of angioimmunoblastic T-cell lymphoma cases, provided further support for this theory.
  • To determine the specifity of this marker for angioimmunoblastic T-cell lymphoma, we evaluated CXCL13 expression in 26 nodal-based peripheral T-cell lymphomas and 14 lymph nodes showing paracortical lymphoid hyperplasia.
  • By WHO classification criteria, 20 of the lymphoma cases were considered peripheral T-cell lymphoma, unspecified, and six were reclassified as angioimmunoblastic T-cell lymphoma after immunohistochemical detection of disorganized follicular dendritic cell meshworks.
  • Combining the results of our studies, 31 of 35 angioimmunoblastic T-cell lymphoma cases (89%) showed CXCL13 expression, in contrast to two out of 20 peripheral T-cell lymphoma, unspecified cases (10%).
  • The two peripheral T-cell lymphoma, unspecified cases that were positive for CXCL13 showed a Lennert lymphoma-like histology.
  • While these cases did not meet all histologic criteria for angioimmunoblastic T-cell lymphoma, they did show an increase in EBV-positive B cells, suggesting they may be histologic variants of angioimmunoblastic T-cell lymphoma.
  • In conclusion, CXCL13 expression is a distinctive feature of angioimmunoblastic T-cell lymphoma, providing further support for the germinal center T-helper cell as the cell of origin for this neoplasm.
  • Given its specificity when compared to cases of peripheral T-cell lymphoma, unspecified as well as paracortical lymphoid hyperplasia, it may be a useful marker in the diagnosis of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Chemokines, CXC / metabolism. Germinal Center / metabolism. Immunoblastic Lymphadenopathy / metabolism. Lymphoma, Follicular / metabolism. Lymphoma, T-Cell, Peripheral / metabolism. T-Lymphocytes, Helper-Inducer / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Chemokine CXCL13. Diagnosis, Differential. Humans. Pseudolymphoma / metabolism. Pseudolymphoma / pathology. Up-Regulation

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mod Pathol. 2007 Feb;20(2):277. Attygale, Ayoma D [corrected to Attygalle, Ayoma D]
  • (PMID = 16680156.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC
  •  go-up   go-down


6. Troxell ML, Schwartz EJ, van de Rijn M, Ross DT, Warnke RA, Higgins JP, Natkunam Y: Follicular dendritic cell immunohistochemical markers in angioimmunoblastic T-cell lymphoma. Appl Immunohistochem Mol Morphol; 2005 Dec;13(4):297-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell immunohistochemical markers in angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma is characterized by a paracortical proliferation of medium to large neoplastic T cells, often with clear cytoplasm, in a background of arborizing high endothelial venules, many surrounded by follicular dendritic cells (FDCs).
  • The authors stained a collection of 45 angioimmunoblastic T-cell lymphomas with CD21, CD23, CNA.42, cystatin A, and fascin for direct comparison of FDC staining characteristics in this setting.
  • CD21 highlighted the expected dendritic network of cell processes, within residual follicles and outside of follicles, often adjacent to proliferating vessels.
  • Cystatin A stained the cytoplasm of follicular dendritic cells within and outside of follicles; however, staining was often not sharply localized to dendritic cell processes, and scoring was further complicated by reactivity with other cell types in over half of the cases.
  • Likewise, fascin stained a variety of cell types, including strong staining of interdigitating dendritic-like cells, moderate staining of endothelial cells, and only weak staining of follicular dendritic cells within and outside of follicles.
  • Thus, CD21 remains the most reliable marker of follicular dendritic cells in angioimmunoblastic T-cell lymphoma.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280657.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Carrier Proteins; 0 / Cystatins; 0 / Cysteine Proteinase Inhibitors; 0 / Microfilament Proteins; 0 / Receptors, Complement 3d; 0 / Receptors, IgE; 146808-54-0 / fascin
  •  go-up   go-down


7. Ren YL, Hong L, Nong L, Zhang S, Li T: [Clinicopathologic, immunohistochemical and molecular analysis in 15 cases of angioimmunoblastic T-cell lymphomas]. Beijing Da Xue Xue Bao; 2008 Aug 18;40(4):352-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic, immunohistochemical and molecular analysis in 15 cases of angioimmunoblastic T-cell lymphomas].
  • OBJECTIVE: To evaluate angioimmunoblastic T-cell lymphoma(AITL) completely, we gave injdepth investigation of histopathological features, specific immunochemical markers, antigen receptor gene rearrangements and in situ hybridization for Epstein-Barr virus (EBV).
  • Polymerase chain reaction for immunoglobulin heavy chain (IgH) and T cell receptor gamma (TCRgamma) rearrangements and in situ hybridization for Epstein-Barr virus encoded RNA (EBER-1) were performed.
  • CD21 expression exihibited extrafollicular expansion of follicular dendritic cell meshworks in 11 cases (73.3%), partially with a tendency of perivascular distribution.
  • Among the four cases with large B cell proliferation, three were EBV-positive.
  • Only when we recognize such diversity, can we reasonably apply and properly evaluate immunochemical markers and molecular techniques, and thus give a correct diagnosis.
  • [MeSH-major] Gene Rearrangement, T-Lymphocyte. Immunoblastic Lymphadenopathy. Lymphoma, T-Cell, Peripheral
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / pathology. Female. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Male. Middle Aged. Receptors, Antigen, T-Cell, gamma-delta / genetics. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677379.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


8. Willenbrock K, Bräuninger A, Hansmann ML: Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol; 2007 Sep;138(6):733-9
Genetic Alliance. consumer health - B-Cell Lymphomas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases.
  • Secondary lymphomas occurring in the setting of angioimmunoblastic T-cell lymphoma (AILT) are considered to be rare.
  • A previous study detected a dysregulated hypermutation process in B-cells of AILT.
  • The present study aimed at estimating the frequency of B-cell lymphomas in AILT.
  • By studying the expression of EBV and activation-induced cytidine deaminase (AID) as an indicator of hypermutating cells, we assessed whether B-cell lymphoproliferations in AILT were strictly associated with EBV and whether hypermutation might contribute to lymphomagenesis.
  • Among 161 cases of AILT, diagnosed between 1996 and 2005 at the lymph node registry, Frankfurt, Germany, 19 cases were detected that also had B-cell non-Hodgkin lymphoma (NHL) and two cases had classical Hodgkin lymphoma (HL).
  • AID was expressed in AILT in large cells disseminated in the tissue, implying that the process of somatic hypermutation is ongoing in AILT, although the GC architecture is disrupted.
  • This might be relevant in the development of secondary lymphomas.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human. Lymphoma, B-Cell / virology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] B-Lymphocytes / pathology. Biomarkers, Tumor / analysis. Cell Proliferation. Clone Cells. Cytidine Deaminase / analysis. DNA-Binding Proteins / analysis. Gene Rearrangement, B-Lymphocyte. Humans. Immunohistochemistry. In Situ Hybridization. Neprilysin / analysis. Polymerase Chain Reaction / methods. RNA, Viral / analysis. Somatic Hypermutation, Immunoglobulin. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672882.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Viral; EC 3.4.24.11 / Neprilysin; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


9. Murakami YI, Yatabe Y, Sakaguchi T, Sasaki E, Yamashita Y, Morito N, Yoh K, Fujioka Y, Matsuno F, Hata H, Mitsuya H, Imagawa S, Suzuki A, Esumi H, Sakai M, Takahashi S, Mori N: c-Maf expression in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol; 2007 Nov;31(11):1695-702
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Maf expression in angioimmunoblastic T-cell lymphoma.
  • We previously examined c-Maf expression in various T-cell lymphomas by reverse-transcription polymerase chain reaction and found extremely elevated c-Maf levels in angioimmunoblastic T-cell lymphoma (AILT).
  • In this study, we examined T-cell lymphomas for c-Maf and cyclin expression immunohistochemically.
  • Of 93 cases of T-cell lymphomas we investigated in the current study, c-Maf expression was seen in 23 out of 31 cases of AILT, 3 out of 11 of adult T-cell leukemia/lymphoma, 4 out of 19 of peripheral T-cell lymphoma, unspecified [PTCL(U)], and 0 out of 11 cases of mycosis fungoides, 0 out of 11 of anaplastic large cell lymphoma, and 1 out of 10 of extranodal NK/T-cell lymphoma, nasal type.
  • Double immunostaining in AILT revealed that the majority of c-Maf-positive cells were also positive for CD43 (MT1), CD45RO (UCHL-1), and CD4 but were negative for CD20 (L26).
  • Additionally, cyclins D1 and D2, which stimulate cell cycle progression, were overexpressed in a large number of the c-Maf-positive AILT samples.
  • Quantitative reverse-transcription polymerase chain reaction analysis also showed that c-Maf was overexpressed in 8/31 cases of AILT, 0/19 cases of PTCL(U), 0/11 cases of anaplastic large cell lymphoma, 0/10 cases of extranodal NK/T-cell lymphoma, nasal type, and 2/8 cases of multiple myeloma, presenting significant difference between AILT and PTCL(U) (P=0.016, chi test).
  • These findings strongly suggest that CD4-positive neoplastic T cells in AILT show c-Maf expression and provide new insight into the pathogenesis of AILT suggesting c-Maf to be a useful diagnostic marker for AILT.
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunoblastic Lymphadenopathy / metabolism. Lymphoma, T-Cell / chemistry. Proto-Oncogene Proteins c-maf / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059226.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD4; 0 / Antigens, CD43; 0 / Biomarkers, Tumor; 0 / CCND2 protein, human; 0 / Cyclin D; 0 / Cyclin D2; 0 / Cyclins; 0 / MAF protein, human; 0 / Proto-Oncogene Proteins c-maf; 0 / RNA, Messenger; 0 / UN1 sialoglycoprotein, human; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


10. Hawley RC, Cankovic M, Zarbo RJ: Angioimmunoblastic T-cell lymphoma with supervening Epstein-Barr virus-associated large B-cell lymphoma. Arch Pathol Lab Med; 2006 Nov;130(11):1707-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with supervening Epstein-Barr virus-associated large B-cell lymphoma.
  • Patients with angioimmunoblastic T-cell lymphoma can have profound immune dysfunction and immunodeficiency.
  • Epstein-Barr virus-driven B-cell lymphoid proliferation can occur in angioimmunoblastic T-cell lymphoma, as in other immunodeficiency states.
  • However, few cases of Epstein-Barr virus-positive B-cell lymphoma arising in patients with preexisting angioimmunoblastic T-cell lymphoma have been reported.
  • We report a case of angioimmunoblastic T-cell lymphoma in which diffuse large B-cell lymphoma developed 56 months after the diagnosis of angioimmunoblastic T-cell lymphoma.
  • The patient survived for 9 years after the initial diagnosis of angioimmunoblastic T-cell lymphoma, and molecular studies performed on multiple biopsy specimens during this period revealed the dynamic nature of clonal lymphoid expansion.
  • Epstein-Barr virus latent membrane protein 1 and Epstein-Barr virus-encoded RNA were detected in the diffuse large B-cell lymphoma, suggesting that Epstein-Barr virus may have played a role in the pathogenesis of the diffuse large B-cell lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / pathology. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076535.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


11. Zheng YY, Chen G, Zhou XG, Zhang SH, Zhang YN: [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):173-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma].
  • OBJECTIVE: To study the morphologic and immunophenotypic features of angioimmunoblastic T-cell lymphoma (AITL), as well as the origin of the proliferative follicular dendritic cells (FDCs) in AITL.
  • Cases of peripheral T-cell lymphoma, unspecified, extranodal NK/T-cell lymphoma, nasal-type, enteropathy-type T-cell lymphoma, anaplastic large cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma and reactive lymphoid proliferation were selected as controls.
  • RESULTS: Amongst the 29 cases of AITL studied, 75.9% (22/29) showed aberrant expression of CD10, while all except one of the controlled cases were negative, 82.8% (24/29) of the AITL cases expressed CXCL13, while all cases of peripheral T-cell lymphoma, unspecified were negative.
  • As for bcl-6 staining, although the highest percentage of bcl-6-positive cells was observed in AITL, the expression pattern was not useful in differentiating AITL from peripheral T-cell lymphoma, unspecified and lymphoid reaction.
  • Two of the cases, which contained obvious germinal centers, had the follicular dendritic cell meshwork extending beyond the lymphoid follicles.
  • [MeSH-major] Chemokine CXCL13 / metabolism. Dendritic Cells, Follicular / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neprilysin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575853.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


12. Lachenal F: [Angioimmunoblastic T-cell lymphoma]. Presse Med; 2007 Nov;36(11 Pt 2):1655-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma].
  • [Transliterated title] Lymphomes T angio-immunoblastiques.
  • Angioimmunoblastic T-cell lymphoma most often affects the elderly.
  • Patients present with generalized lymphadenopathy and systemic symptoms; half also have hepatomegaly, splenomegaly and a rash.
  • Lymph node biopsy is needed to confirm this diagnosis.
  • Genetic analysis that reveals a monoclonal T-cell population is also relevant.
  • Autologous stem cell transplantation is proposed to the youngest.
  • [MeSH-major] Immunoblastic Lymphadenopathy. Lymphoma, T-Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587541.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 79
  •  go-up   go-down


13. Jones B, Vun Y, Sabah M, Egan CA: Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma. Australas J Dermatol; 2005 Aug;46(3):187-91
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma.
  • A 67-year-old man presented with a history of lymphadenopathy, fevers and separate skin eruptions of erythrodermic spongiotic dermatitis initially and subsequent toxic epidermal necrolysis.
  • Initial lymph node biopsies showed non-specific granulomatous changes, and skin biopsies and bone marrow aspirate were not diagnostic.
  • Due to persisting lymphadenopathy, further lymph node biopsy led to the diagnosis of angioimmunoblastic T-cell lymphoma, a rare form of peripheral T-cell lymphoma with a poor prognosis.
  • At the time of diagnosis his condition deteriorated rapidly and he died soon after.
  • [MeSH-major] Head and Neck Neoplasms / complications. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications. Stevens-Johnson Syndrome / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008654.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


14. Saito A, Miyazawa Y, Isoda A, Hatsumi N, Matsumoto M, Kojima M, Sawamura M: [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)]. Rinsho Ketsueki; 2008 Feb;49(2):82-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)].
  • We retrospectively analyzed the clinical course and prognosis of 11 patients with angioimmunoblastic T-cell Lymphoma (AILT).
  • The disease can be classified into three categories based on histological findings: 3 cases of AILT with hyperplastic germinal centers, 4 cases of typical AILT, and 4 cases of AILT with numerous clear cells.
  • As the initial therapy, 10 patients received combination chemotherapy and only 1 patient received autologous peripheral blood stem cell transplantation.
  • Patients with AILT demonstrating hyperplastic germinal centers and no bone marrow infiltration were able to achieve long-term survival.
  • The survival time of AILT demonstrated a wide range.
  • [MeSH-major] Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341037.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Oki M, Isozaki M, Nakamura N, Kikuchi A, Tsuchiya T, Arbogast P, Ogawa Y, Ando K: A multivariate analysis for the survival of nodal peripheral T-cell lymphoma (PTCL). J Clin Oncol; 2009 May 20;27(15_suppl):e19521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multivariate analysis for the survival of nodal peripheral T-cell lymphoma (PTCL).
  • : e19521 Background: Nodal peripheral T-cell lymphoma (PTCL) is uncommon lymphoma with various subtypes and poor prognosis.
  • However, the superiority of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has remained inconclusive.
  • We conducted a retrospective study of fifty six patients with three major nodal PTCL, histologically classified as PTCL-not specified (NOS, n=29), angioimmunoblastic T-cell lymphoma (AITL, n=19), and ALK-negative anaplastic large cell lymphoma (ALCL, n=8) who underwent ASCT (n=14) or not (n=42) after CT in Tokai University Hospital, Ebina General Hospital, and Hadano Red Cross Hospital, Kanagawa, Japan between 1997 and 2008.
  • METHODS: Retrospective, multicenter cohort study by time-dependent or non-time-dependent multivariate survival analysis with Cox proportional hazard regression.
  • In non-time-dependent analysis, both ASCT and sIL-R were significant prognostic factors for overall survival (OS).
  • On the other hand, ASCT was only important effect on progression-free survival (PFS) by non-time-dependent analysis, which HR was 0.20 (95%CI: 0.07-0.55, p=0.02).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Vigil CE, Ayala E, Sokol L: Autologous stem cell transplant in peripheral T cell lymphomas: Single institution 10-year retrospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e19538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplant in peripheral T cell lymphomas: Single institution 10-year retrospective analysis.
  • : e19538 Background: Peripheral T-cell lymphoma is a rare entitydisease, compromising 10% of non-Hodgkin's lymphoma worldwide and 5% of all lymphoid neoplasms in the United States.
  • High-dose chemotherapy followed by autologous haematopoietic stem cell transplantation, has been explored in recent years with little experiences.
  • METHODS: A retrospective analysis on patients with diagnosis of peripheral T-cell lymphoma receiving autologous stem cell transplant was conducted (January 1997 to July 2008).
  • The patients were stratified according to their International Prognostic Index (IPI), disease status at the time of transplant and histology type.
  • RESULTS: Twenty-nine subjects were identified, with a median age of 51; 13 patients had Anaplastic T cell, 18 patient had PTCL-nos, and 6 patients with angioimmunoblastic T cell lymphoma.
  • Seventeen patients (58.62%) presented with an aa IPI score greater than 2.4 patients were in complete remission, 15 at first relapse, 4 in greater than 1 episode, and 6 with refractory disease at the time of transplantion.Kaplan Meier overall survival (OS) 72 and relapse free survival (RFS) was 62 at 1 year respectively.
  • A multivariate analysis and new risk stratification based on the IPI score system and disease status at time of transplant were employed.
  • CONCLUSIONS: The status at time of transplant with new methods for evaluation of minimal residual disease may help in assessing outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961010.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Halene S, Zieske A, Berliner N: Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat Clin Pract Oncol; 2006 Mar;3(3):165-8; quiz 169
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab.
  • She had previously had a positive protein derivative test with a negative chest X-ray; her medical history was also remarkable for a mitral valve prolapse.
  • Initial symptoms resolved spontaneously without therapy, but fever recurred with associated arthralgias, myalgias, diffuse and worsening lymphadenopathy, splenomegaly, and bilateral pulmonary infiltrates.
  • DIAGNOSIS: Angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Immunoblastic Lymphadenopathy / drug therapy. Lymphoma, T-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520806.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


18. Wang FX, Zhang XJ, Pan L, Qiao SK, Guo XL, Dong ZR: [Angioimmunoblastic T-cell lymphoma with autoimmune hemolytic anemia and pure red cell aplasia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug;15(4):862-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma with autoimmune hemolytic anemia and pure red cell aplasia].
  • Angioimmunoblastic T-cell lymphoma (AILT) is a peripheral T-cell lymphoma often complicated autoimmune phenomena such as autoimmune cytopenia, and is a truly rare type of NHL.
  • In order to investigate the clinical features, pathological manifestation of this lymphoma, and to explore its therapy protocol, a 37-years old patient with AILT was investigated.
  • The warm type autoimmune hemolytic anemia (AIHA) and pure red cell aplasia (PRCA) were co-existed.
  • In conclusion, the AITL patient complicated with AIHA and PRCA was successfully diagnosed, the lymphonode biopsy and bone marrow smear showed more significant, the chemotherapy protocol of CHOP-E can give some effect to cure such angioimmunoblastic T cell lymphoma.


19. Miura N, Suzuki K, Yoshino M, Kitagawa W, Yamada H, Ohtani H, Joh K, Imai H: Acute renal failure due to IgM-lambda glomerular thrombi and MPGN-like lesions in a patient with angioimmunoblastic T-Cell lymphoma. Am J Kidney Dis; 2006 Jul;48(1):e3-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal failure due to IgM-lambda glomerular thrombi and MPGN-like lesions in a patient with angioimmunoblastic T-Cell lymphoma.
  • A 70-year-old man with angioimmunoblastic T-cell lymphoma developed acute renal failure.
  • These findings suggest that cryoglobulin, which consists of monoclonal IgM-lambda, induced glomerular thrombi and acute renal failure in a patient with angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications. Thrombosis / etiology. Thrombosis / immunology

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16797380.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M
  •  go-up   go-down


20. Noorali S, Nasir MI, Pervez S: Characterization of angioimmunoblastic T-cell lymphomas (AILT) and its association with Epstein-Barr virus (EBV) in Pakistani patients. J Coll Physicians Surg Pak; 2005 Jul;15(7):404-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of angioimmunoblastic T-cell lymphomas (AILT) and its association with Epstein-Barr virus (EBV) in Pakistani patients.
  • OBJECTIVE: To characterize angioimmunoblastic T-cell lymphoma (AILT) on morphological, immunohistochemical and molecular grounds and its association with Epstein-Barr virus (EBV) in Pakistani patients.
  • PATIENTS AND METHODS: Over a period of 11 years archival biopsy material of 13 AILT cases (lymph nodes), identified on the basis of histological and immunohistochemical criteria, using REAL and WHO classifications, were retrieved from the files of Department of Pathology.
  • Immunophenotyping was carried out by using CD45 (LCA), two T-cell markers CD45RO (UCHL1; monoclonal) and CD3 (polyclonal).
  • Polymerase chain reaction (PCR) was used to assess T-cell clonality for T-cell receptor (TCR)-b, g and immunoglobulin heavy chain (IgH) for FR2 and FR3 regions using primers recognizing conserved sequences of the variable (V), diversity (D) and joining (J) region segments.
  • Association of EBV in AILT cases was studied by PCR and in situ hybridization (ISH).
  • RESULTS: This study showed AILT to constitute 0.71% of all NHLs (non-Hodgkin's lymphoma) [both T and B].
  • All the 13 cases were largely negative for CD20 (L26), a B-cell marker, except few large scattered cells labelling.
  • PCR technique demonstrated clonal gene rearrangement of the TCR-b, g and IgH regions in 3 (23.1%), 7 (53.8%) and 3 (23.1%) AILT cases, respectively out of 13 cases.
  • Association of EBV was seen in 11 out of 13 cases (84.6%) of AILT by PCR.
  • CONCLUSION: The prevalence of AILT in the Pakistani population is slightly lower compared to other studies and that EBV is an etiological agent in pathogenesis of this disease.
  • [MeSH-major] Lymphoma, T-Cell / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197868.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


21. Park BB, Ryoo BY, Lee JH, Kwon HC, Yang SH, Kang HJ, Kim HJ, Oh SY, Ko YH, Huh JR, Lee SS, Nam EM, Park KW, Kim JH, Kang JH, Bang SM, Park S, Kim K, Park K, Suh C, Kim WS: Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma; 2007 Apr;48(4):716-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma.
  • The objective of this retrospective study was to investigate clinical features and treatment outcomes in patients with angioimmunoblastic T-cell lymphoma (AITL), data of which were collected over a 15-year period.
  • At diagnosis, 27 patients (41.5%) presented with malignant pleural effusion, and 22 patients (33.8%) had skin involvement.
  • [MeSH-major] Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / therapy. Neovascularization, Pathologic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anthracyclines / pharmacology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Apr;48(4):645-6 [17454617.001]
  • (PMID = 17454629.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


22. Grogg KL, Morice WG, Macon WR: Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol; 2007 Jun;137(5):416-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma.
  • Bone marrow (BM) biopsy is often performed early in the evaluation of patients with angioimmunoblastic T-cell lymphoma (AITL), and may be the first diagnostic tissue sample; yet the BM histopathology associated with this disease has not been well described.
  • Seven (54%) were involved by AITL, which was characterised by paratrabecular and interstitial polymorphous infiltrates containing cytologically atypical lymphocytes, histiocytes and eosinophils.
  • As in lymph nodes, the lymphomatous infiltrate in some BMs contained numerous small or scattered large B cells, resembling either benign lymphoid aggregates or T cell rich large B cell lymphoma, respectively.
  • When BM biopsy preceded the diagnosis of AITL, these secondary changes were misinterpreted as chronic myeloproliferative disease (n = 2), or plasma cell dyscrasia (n = 2).
  • The spectrum of BM findings in AITL patients is important to recognise for early and accurate diagnosis in this disease.
  • [MeSH-major] Bone Marrow Examination. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] B-Lymphocytes / pathology. Chemokine CXCL13. Chemokines, CXC / analysis. Diagnosis, Differential. Eosinophils / pathology. Histiocytes / pathology. Humans. Immunohistochemistry. Lymphoma, B-Cell / pathology. Neprilysin / analysis. Red-Cell Aplasia, Pure / pathology. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488486.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


23. Merchant SH, Amin MB, Viswanatha DS: Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma: Emphasis on phenotypic aberrancies for early diagnosis. Am J Clin Pathol; 2006 Jul;126(1):29-38

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma: Emphasis on phenotypic aberrancies for early diagnosis.
  • The morphologic features and immunophenotype of diagnostic nodal and bone marrow biopsy specimens were reviewed in 29 well-established cases of angioimmunoblastic T-cell lymphoma (AILT).
  • All cases showed a characteristic polymorphous lymphoid and inflammatory cell infiltrate along with stromal-vascular changes.
  • Unique architectural changes, including extranodal extension (83%), follicular dendritic cell proliferation (93%), and a distinctly marginalized distribution of residual B cells (67%) were observed.
  • Subsets of T cells with immunophenotypic abnormalities (CD10 coexpression or loss of pan-T-cell antigens CD3 and CD7) were identified in a majority of cases (96%).
  • Significantly, these morphologic and phenotypic features were seen irrespective of the presence of an overt lymphomatous pattern.
  • Our results indicate that unique morphologic alterations and subsets of phenotypically aberrant T cells are present consistently in nearly all cases of AILT, including morphologically less definitive biopsy specimens.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Immunophenotyping / methods. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Bone Marrow / metabolism. Bone Marrow / pathology. DNA, Neoplasm / analysis. Dendritic Cells, Follicular / metabolism. Dendritic Cells, Follicular / pathology. Early Diagnosis. Female. Flow Cytometry. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Polymerase Chain Reaction. T-Lymphocyte Subsets / metabolism. T-Lymphocyte Subsets / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753608.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


24. Zhao WL, Liu YY, Plassa F, Jin XL, Wang L, Janin A, Shen ZX: [Analysis of overexpression of vascular endothelial growth factor-C in patients with angioimmunoblastic T-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2007 Oct;28(10):664-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of overexpression of vascular endothelial growth factor-C in patients with angioimmunoblastic T-cell lymphoma].
  • OBJECTIVE: To explore the vascular endothelial growth factor-C (VEGF-C) expression and its clinical significance in malignant lymphoma.
  • METHODS: Lymphoma cells were isolated by laser microdissection.
  • VEGF-C expression in lymphoma tissue and microdissected lymphoma cells was measured by realtime quantitative PCR.
  • RESULTS: Comparing with that in 8 patients with reactive lymphocyte hyperplasia, VEGF-C was overexpressed in angioimmunoblastic T-cell lymphoma, both in lymphoma tissue (n = 18, P = 0.0020) and in microdissected lymphoma cells (n = 10, P < 0.0001).
  • CONCLUSION: The value of VEGF-C expression might be a biomarker of disease progression in angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / metabolism. Lymphoma, T-Cell / metabolism. Vascular Endothelial Growth Factor C / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399170.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


25. Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, Geng H, Deffenbacher K, Smith L, Dybkaer K, Nakamura S, Seto M, Delabie J, Berger F, Loong F, Au WY, Ko YH, Sng I, Armitage JO, Chan WC, International Peripheral T-Cell Lymphoma Project: Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood; 2010 Feb 4;115(5):1026-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.
  • Peripheral T-cell lymphoma (PTCL) is often challenging to diagnose and classify.
  • Gene expression profiling was performed on 144 cases of PTCL and natural killer cell lymphoma and robust molecular classifiers were constructed for angioimmunoblastic T-cell lymphoma (AITL), anaplastic lymphoma kinase-positive (ALK(+)) anaplastic large-cell lymphoma (ALCL), and adult T-cell leukemia/lymphoma.
  • Many of the pathologic features and substantial components of the molecular signature of AITL are contributed by the follicular dendritic cells, B-cell, and other stromal components.
  • The expression of Th17-associated molecules in ALK(+) ALCL was noted and may represent aberrant activation of Th17-cell differentiation by abnormal cytokine secretion.
  • Adult T-cell leukemia/lymphoma has a homogeneous molecular signature demonstrating high expression of human T-lymphotropic virus type 1-induced genes.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):317-26 [10830738.001]
  • [Cites] J Immunol. 2004 Feb 15;172(4):2006-10 [14764663.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] PLoS Biol. 2004 Apr;2(4):E108 [15094809.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5154-7 [15100251.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):605-13 [15289861.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):334-43 [15480768.001]
  • [Cites] Nouv Rev Fr Hematol. 1990;32(1):39-41 [2140884.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Blood. 1997 Feb 1;89(3):948-56 [9028326.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2296-301 [9196143.001]
  • [Cites] J Pathol. 1997 Dec;183(4):432-9 [9496260.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):703-11 [9674744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7529-39 [15569983.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1204-13 [15471956.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):206-14 [15668271.001]
  • [Cites] Br J Haematol. 2005 May;129(3):366-72 [15842660.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):440 [15925824.001]
  • [Cites] Hum Pathol. 2005 May;36(5):494-504 [15948116.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1284-93 [16160469.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2254-63 [16270046.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1560-70 [16288225.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Blood. 2006 Jul 1;108(1):218-27 [16527888.001]
  • [Cites] J Clin Invest. 2006 Dec;116(12):3171-82 [17111047.001]
  • [Cites] Hematol Oncol. 2006 Dec;24(4):175-80 [16783841.001]
  • [Cites] J Immunol. 2007 Jan 15;178(2):817-28 [17202343.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Expert Opin Ther Targets. 2007 May;11(5):613-24 [17465721.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3321-9 [17577022.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1382-7 [17693651.001]
  • [Cites] BMC Genomics. 2007;8:230 [17623099.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10703-10 [18006812.001]
  • [Cites] Handb Exp Pharmacol. 2008;(181):151-60 [18071945.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Nat Immunol. 2009 Jan;10(1):48-57 [19011627.001]
  • [Cites] Nat Rev Immunol. 2009 Jan;9(1):39-46 [19079134.001]
  • [Cites] Arthritis Rheum. 2009 Mar;60(3):750-9 [19248112.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4016-26 [19131553.001]
  • [Cites] Curr Hematol Malig Rep. 2006 Jun;1(2):129-36 [20425343.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):525-33 [11169934.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4333-43 [11970975.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16831-6 [11877449.001]
  • [Cites] J Mol Diagn. 2002 Aug;4(3):137-43 [12169674.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 [12509396.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Blood. 2004 Jan 1;103(1):236-41 [12958063.001]
  • [CommentIn] Blood. 2010 Feb 4;115(5):919-20 [20133472.001]
  • (PMID = 19965671.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE19069
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; United States / NCI NIH HHS / CA / CA36727; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / P30 CA036727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2817630
  •  go-up   go-down


26. Tripodo C, Gri G, Piccaluga PP, Frossi B, Guarnotta C, Piconese S, Franco G, Vetri V, Pucillo CE, Florena AM, Colombo MP, Pileri SA: Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol; 2010 Aug;177(2):792-802
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma.
  • Reports focusing on the immunological microenvironment of peripheral T-cell lymphomas (PTCL) are rare.
  • Here we studied the reciprocal contribution of regulatory (Treg) and interleukin-17-producing (Th17) T-cells to the composition of the lymphoma-associated microenvironment of angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified on tissue microarrays from 30 PTCLs not otherwise specified and 37 AITLs.
  • We found that Th17 but not Treg cells were differently represented in the two lymphomas and correlated with the amount of mast cells (MCs) and granulocytes, which preferentially occurred in the cellular milieu of AITL cases.
  • [MeSH-major] Immunoblastic Lymphadenopathy / immunology. Inflammation / immunology. Lymphoma, T-Cell / immunology. Mast Cells / immunology. Th17 Cells / immunology. Tumor Microenvironment

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):217-23 [17306521.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10703-10 [18006812.001]
  • [Cites] Annu Rev Immunol. 2008;26:705-39 [18370925.001]
  • [Cites] Blood. 2008 May 1;111(9):4463-70 [18292286.001]
  • [Cites] Nat Rev Immunol. 2008 Jun;8(6):478-86 [18483499.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Am J Clin Pathol. 2008 Oct;130(4):613-9 [18794055.001]
  • [Cites] Nat Immunol. 2008 Nov;9(11):1215-23 [18936782.001]
  • [Cites] J Clin Pathol. 2008 Nov;61(11):1160-7 [18755717.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Dec;68(3):264-71 [18684638.001]
  • [Cites] Immunity. 2008 Nov 14;29(5):771-81 [18993084.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:272-9 [19074096.001]
  • [Cites] Mucosal Immunol. 2008 Nov;1 Suppl 1:S43-6 [19079228.001]
  • [Cites] Oncologist. 2008 Dec;13(12):1246-54 [19056856.001]
  • [Cites] Haematologica. 2009 Jan;94(1):127-30 [19029148.001]
  • [Cites] Immunity. 2009 Jan 16;30(1):92-107 [19119024.001]
  • [Cites] Immunity. 2009 Mar 20;30(3):324-35 [19303387.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):239-52 [19279573.001]
  • [Cites] Nat Rev Rheumatol. 2009 Jun;5(6):325-31 [19434074.001]
  • [Cites] Curr Opin Immunol. 2009 Jun;21(3):274-80 [19524429.001]
  • [Cites] Am J Hematol. 2009 Jul;84(7):435-8 [19484731.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5619-22 [19567669.001]
  • [Cites] Blood. 2009 Aug 6;114(6):1141-9 [19470694.001]
  • [Cites] Immunobiology. 2009;214(9-10):835-42 [19628296.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):665-74 [19693095.001]
  • [Cites] N Engl J Med. 2009 Aug 27;361(9):888-98 [19710487.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4197-203 [19636021.001]
  • [Cites] J Immunol. 2009 Oct 1;183(7):4169-75 [19767566.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2639-48 [19643985.001]
  • [Cites] Blood. 2009 Oct 1;114(14):2936-44 [19671921.001]
  • [Cites] Crit Rev Oncol Hematol. 2009 Nov;72(2):125-43 [19233683.001]
  • [Cites] Hum Pathol. 2010 Jan;41(1):79-87 [19740519.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1026-36 [19965671.001]
  • [Cites] Trends Immunol. 2010 Mar;31(3):97-102 [20149743.001]
  • [Cites] Blood. 2010 Apr 8;115(14):2810-7 [20101023.001]
  • [Cites] Br J Haematol. 2010 Mar;148(5):673-89 [19961485.001]
  • [Cites] J Rheumatol. 2000 Apr;27(4):1087-90 [10782842.001]
  • [Cites] J Pathol. 2003 Feb;199(2):201-7 [12533833.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3037-45 [12626558.001]
  • [Cites] Leuk Res. 2003 Aug;27(8):677-82 [12801524.001]
  • [Cites] Lab Invest. 2004 Nov;84(11):1512-9 [15311211.001]
  • [Cites] Leukemia. 1996 Sep;10(9):1504-8 [8751470.001]
  • [Cites] Acta Haematol. 2005;114(2):108-12 [16103635.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):295-307 [16557261.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • (PMID = 20595635.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CXCL13; 0 / Cytokines; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-17; 0 / Interleukin-6
  • [Other-IDs] NLM/ PMC2913370
  •  go-up   go-down


27. Khokhar FA, Payne WD, Talwalkar SS, Jorgensen JL, Bueso-Ramos CE, Medeiros LJ, Vega F: Angioimmunoblastic T-cell lymphoma in bone marrow: a morphologic and immunophenotypic study. Hum Pathol; 2010 Jan;41(1):79-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma in bone marrow: a morphologic and immunophenotypic study.
  • Angioimmunoblastic T-cell lymphoma is known to frequently involve bone marrow.
  • However, the histologic and immunophenotypic features of angioimmunoblastic T-cell lymphoma at this site are poorly defined.
  • We assessed 27 bone marrow specimens involved by angioimmunoblastic T-cell lymphoma from 20 patients.
  • Flow cytometry immunophenotyping revealed a CD3+CD10+ T-cell population in 2 (25%) of 8 cases assessed.
  • We conclude that the recognition and classification of angioimmunoblastic T-cell lymphoma in bone marrow are made difficult by the uncommon expression of CD10 (25%), rarity of follicular dendritic cells, and lack of CXCL13 expression at this site.
  • By contrast, programed death-1 immunohistochemical staining and double labeling using antibodies specific for BCL-6 and CD3 were helpful in appreciating the follicular T-helper cell immunophenotype of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Bone Marrow Cells / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Chemokine CXCL13 / metabolism. DNA-Binding Proteins / metabolism. Female. Flow Cytometry. Humans. Immunophenotyping. Intercellular Signaling Peptides and Proteins / metabolism. Male. Middle Aged. Neprilysin / metabolism. Programmed Cell Death 1 Ligand 2 Protein. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19740519.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / DNA-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / PDCD1LG2 protein, human; 0 / Programmed Cell Death 1 Ligand 2 Protein; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


28. Lee Y, Lee KW, Kim JH, Bang SM, Lee JS, Park BB, Kim WS, Suh C, Kang JH, Ryoo BY, Lee JH, Shin DB: Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma. Korean J Intern Med; 2008 Mar;23(1):30-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma.
  • BACKGROUND/AIMS: Epstein-Barr virus (EBV) is involved in the pathogenesis of angioimmunoblastic T-cell lymphoma (AILT), but its precise role and prognostic impact are not clear.
  • This study aimed to evaluate the incidence of EBV-postitivity in the tumor and bone marrow (BM) samples from AILT patients, and their correlations with the clinical variables and patient survival.
  • METHODS: Seventy AILT cases were identified over a period of 8 years.
  • In 13 (48%) patients, gross tumor involvement was recognized by hematoxylin-eosin staining at the time of diagnosis.
  • CONCLUSIONS: EBV-positivity of tumor had no impact on the prognosis of AILT patients.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Immunoblastic Lymphadenopathy / virology. Lymphoma, T-Cell / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):860-8 [17509983.001]
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):805-11 [12153168.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Lancet Infect Dis. 2003 Mar;3(3):131-40 [12614729.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] J Korean Med Sci. 2004 Apr;19(2):229-33 [15082896.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Int J Cancer. 1976 Feb 15;17(2):177-81 [175027.001]
  • [Cites] Blood. 1991 Feb 15;77(4):799-808 [1847084.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Blood. 1992 Jul 15;80(2):484-91 [1320954.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1804-12 [1327284.001]
  • [Cites] Histopathology. 1993 Feb;22(2):145-9 [8384155.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1063-9 [16079105.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1192-6 [16154842.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:260-6 [16304390.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):466-75; quiz 527 [16931587.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):716-22 [17454629.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • (PMID = 18363277.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2686953
  •  go-up   go-down


29. Baseggio L, Berger F, Morel D, Delfau-Larue MH, Goedert G, Salles G, Magaud JP, Felman P: Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma. Leukemia; 2006 Feb;20(2):296-303

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma.
  • In most cases of lymphomas with blood dissemination, the careful cytological analysis of peripheral blood smears provides a rapid orientation to diagnosis, even if the final subtyping is achieved by histology and eventually other techniques.
  • Here, we evaluated if the analysis of blood smears may suggest the blood dissemination of angioimmunoblastic T-cell lymphoma (AITL) and if CD10 expression on neoplastic T cells, as recently reported on AITL, may contribute to the diagnosis.
  • In all, 11 lymph nodes and six peripheral blood samples from 12 patients with AITL were studied using four-colour flow cytometry associated to histological, cytological and molecular data.
  • Interestingly, all blood smears showed atypical lymphoid cells and a fraction of T cells expressed CD10 with a mean percentage of 18.75% (range 5.00-47.00%), regardless of lymphocytosis level and of rate of CD10 T cells in corresponding lymph node.
  • In contrast, in all control samples (100), none CD10-positive T cell was identified.
  • Therefore, they ought to be explored in further studies when aggressive lymphoma, in particular with lymphopenia and circulating atypical cells, is suspected.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Neoplastic Cells, Circulating / immunology. Neoplastic Cells, Circulating / pathology. Neprilysin / biosynthesis. T-Lymphocytes / immunology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Flow Cytometry. Gene Rearrangement. Genes, T-Cell Receptor gamma / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16341050.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


30. Skugor ND, Perić Z, Vrhovac R, Radić-Kristo D, Kardum-Skelin I, Jaksić B: Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma. Coll Antropol; 2010 Mar;34(1):241-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
  • Relatively few cases of Epstein-Barr (EBV)-positive B-cell lymphomas arising in patients with angioimmunoblastic T-cell lymphoma (AITL) have been reported.
  • We report a case of AITL in which diffuse large B-cell lymphoma arose 13 months after the initial diagnosis of AITL.
  • In a 36-year-old female patient, evaluated for moderate leukocytosis, peripheral and abdominal lymphadenopathy AITL was diagnosed in March 2008, based on results of fine-needle aspiration cytology (FNAC) of the enlarged cervical and supraclavicular lymph nodes.
  • The diagnosis was also confirmed by immunophenotyping and histopathology of the cervical lymph nodes.
  • The patient initially recieved FED chemotherapy (fludarabine, cyclophosphamide, dexamethasone) followed by elective autologous hematopoietic stem cell transplantation.
  • In April 2009 the patient was hospitalized because of fever, pancytopenia, hyperbilirubinemia and peripheral lymphadenopathy.
  • CHOP-R chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) was then administered, resulting in good partial response of the disease.
  • Reduced intensity allogeneic stem cell transplantation performed thereafter, resulted in complete remission of the disease.
  • AITL is a rare lymphoproliferative disorder in which the neoplastic T-cells represent the minority of the lymph node cell population and almost all cases harbor EBV-infected B-cells.
  • Various authors postulated that immunodeficiency in AITL patients together with immunosuppressive effects of cytotoxic drugs, may be responsible for EBV-induced proliferation of latently or newly EBV-infected B-cells with eventual clonal selection and progression to aggressive B-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neoplasms, Second Primary / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432757.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


31. Liao YL, Chang ST, Kuo SY, Lin SH, Chen CK, Chang KM, Chuang SS: Angioimmunoblastic T-cell lymphoma of cytotoxic T-cell phenotype containing a large B-cell proliferation with an undersized B-cell clonal product. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):185-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma of cytotoxic T-cell phenotype containing a large B-cell proliferation with an undersized B-cell clonal product.
  • Angioimmunoblastic T-cell lymphoma is a nodal peripheral T-cell lymphoma considered to be derived from CD4 follicular helper T cells.
  • We presented the case of a 60-year-old male patient with angioimmunoblastic T-cell lymphoma, in which the neoplastic T cells expressed CD8, bcl-6, and programmed death-1.
  • The results of T-cell receptor gene rearrangement study using the Biomed-2 protocols showed clonal rearrangement with amplicons falling within the expected size ranges.
  • Through cloning, sequencing, and BLAST searches, we confirmed that the FR2/JH amplicon was derived from the IgH rearrangement with a deletion of a short segment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19956067.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD8; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / BCL6 protein, human; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


32. Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A: Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology; 2007 Mar;50(4):498-508
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics.
  • AIMS: To identify distinguishing histological, immunophenotypic and molecular genetic features between angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma (PTL).
  • METHODS: Nodal T-cell lymphomas examined (n =137), included AITL (n = 89), PTL (n = 22), anaplastic large cell lymphoma (n = 16) and 'AITL/PTL indeterminate' (n = 10) with overlapping features between AITL and PTL, showing morphology typical of AITL but lacking follicular dendritic cell expansion.
  • Immunohistochemistry for CD3, CD20, CD21 and CD10, in situ hybridization for Epstein-Barr virus encoded RNA (EBER) and polymerase chain reaction for T-cell and B-cell clonality analysis were performed.
  • Detection of T-cell clonality was significantly higher in AITL (90%) compared with PTLu (59%).
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis
  • [MeSH-minor] Antigens, CD20 / metabolism. Antigens, CD3 / metabolism. B-Lymphocytes / pathology. Clone Cells. Diagnosis, Differential. Gene Rearrangement. Herpesvirus 4, Human / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Immunophenotyping. Neprilysin / metabolism. Polymerase Chain Reaction. RNA, Viral / analysis. Receptors, Antigen, T-Cell, gamma-delta / genetics. Receptors, Complement 3d / metabolism. Sensitivity and Specificity. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448026.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Immunoglobulin Heavy Chains; 0 / RNA, Viral; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


33. Wang SH, Wang QS, Sun L, Li HH, Zhao Y, Jia BJ, Zhang XL, Yu L: [Clinical analysis of 12 patients with angioimmunoblastic T cell lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1208-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 12 patients with angioimmunoblastic T cell lymphoma].
  • To evaluate the clinical, pathological characters and prognosis of patients with angioimmunoblastic T cell lymphoma (AITL), the clinicopathologic features, immunophenotypes, therapy and survival rate of 12 AITL patients which were confirmed by pathologic examination were retrospectively studied.
  • The results indicated that main symptom was observed as general lymphadenopathy, however, 9 patients had fever.
  • The diagnosis of AITL was based on lymph-node biopsy.
  • The histopathologic characteristics of AITL showed the damage of normal lymphnode structure, the proliferation of immunoblastic cells and arborescent super vascularization.
  • All immunophenotypes were mature peripheral T-cellular.
  • In conclusion, most cases of AITL display an aggressive course, therefore, the disease progresses rapidly and has unfavorable prognosis, further studies are required to improve its therapy regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129262.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


34. Rodriguez-Justo M, Attygalle AD, Munson P, Roncador G, Marafioti T, Piris MA: Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. Mod Pathol; 2009 Jun;22(6):753-61
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers.
  • Angioimmunoblastic T-cell lymphoma is an aggressive peripheral T-cell lymphoma whose natural history is not fully understood.
  • The accurate recognition of Angioimmunoblastic T-cell lymphoma with pattern I remains a challenge and therefore the aim of this study is to phenotypically and morphologically characterize this variant with the use of the follicular helper T-cell (T(FH)) markers PD1, CXCL-13 and ICOS.
  • Out of the 88 Angioimmunoblastic T-cell lymphoma cases reviewed, 10 showed hyperplastic follicles.
  • Molecular probe methods for the detection of T-cell and B-cell clonality, as well as in-situ hybridization probes for EBV RNA expression, were carried out to leave no question as to the establishment of the diagnosis in each case.
  • By contrast, CD10 was found to only weakly label the neoplastic T cells, with only 5-10% of the target cell population staining for this marker.
  • Clinically, 8/9 cases presented with stage IIIB/IVB and in 2/10 cases consecutive biopsies showed 'progression' from pattern I to classical Angioimmunoblastic T-cell lymphoma.
  • In conclusion we have shown that the T(FH) cells markers PD1, CXCL13 and ICOS are useful adjuncts in the diagnosis of Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres.
  • PD1 also highlighted the presence of neoplastic cells in the outer zone of lymphoid follicles, suggesting that Angioimmunoblastic T-cell lymphoma (pattern I) may originate from T(FH) cells in this region, in accordance with previous immunological studies.
  • As the majority of cases in our series presented clinically with advanced stage disease, progression from pattern I to classical Angioimmunoblastic T-cell lymphoma may represent histological evolution rather than clinical progression.
  • [MeSH-major] Germinal Center / pathology. Lymph Nodes / pathology. Lymphoma, T-Cell / pathology. T-Lymphocytes, Helper-Inducer / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antigens, Differentiation, T-Lymphocyte / metabolism. Apoptosis Regulatory Proteins / metabolism. Biomarkers, Tumor / immunology. Chemokine CXCL13 / metabolism. Female. Humans. Immunohistochemistry. Inducible T-Cell Co-Stimulator Protein. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Programmed Cell Death 1 Receptor

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329936.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Chemokine CXCL13; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


35. Papadavid E, Panayiotides I, Dalamaga M, Katoulis A, Economopoulos T, Stavrianeas N: Cutaneous involvement in angioimmunoblastic T-cell lymphoma. Indian J Dermatol; 2010 Jul-Sep;55(3):279-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous involvement in angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive non-Hodgkin's nodal peripheral T-cell lymphoma characterized by general lymphadenopathy, night sweats, fever, hepatosplenomegaly, polyclonal hypergammaglobulinemia, and cutaneous involvement.
  • We present a rare case of AITL cutaneous involvement mimicking toxic erythema recurring with AITL relapse and suggesting a precursor of disease progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21063526.001).
  • [ISSN] 1998-3611
  • [Journal-full-title] Indian journal of dermatology
  • [ISO-abbreviation] Indian J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2965920
  • [Keywords] NOTNLM ; Angioimmunoblastic T-cell lymphoma / cutaneous involvement
  •  go-up   go-down


36. Ortonne N, Dupuis J, Plonquet A, Martin N, Copie-Bergman C, Bagot M, Delfau-Larue MH, Gaulier A, Haioun C, Wechsler J, Gaulard P: Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL). Am J Surg Pathol; 2007 Jul;31(7):1068-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL).
  • Skin manifestations of angioimmunoblastic T-cell lymphoma (AITL) are frequent, sometimes as first manifestations of the disease.
  • In the absence of a specific marker for neoplastic cells, diagnosis of AITL in skin biopsies is often difficult.
  • A few CD10 lymphocytes were found in only 2 samples of the AITL group, the identification of which was hampered by the presence of a dermal CD10 cell population with dendritic features.
  • In another case, a diagnosis of cutaneous marginal zone B-cell lymphoma had been proposed.
  • In conclusion, this study shows that neoplastic AITL CXCL13 T cells localize in the skin and that accurate diagnosis of AITL lesions can be done in skin specimens using CXCL13 immunostaining on paraffin-embedded tissues.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Chemokines, CXC / metabolism. Lymphoma, T-Cell, Peripheral / metabolism. T-Lymphocytes / metabolism

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592274.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


37. Sekine R, Ohno N, Uchimura K, Oyaizu N, Tojo A: [Severe systemic edema correlated with serum VEGF titer in a patient with angioimmunoblastic T-cell lymphoma]. Rinsho Ketsueki; 2007 Nov;48(11):1498-502
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Severe systemic edema correlated with serum VEGF titer in a patient with angioimmunoblastic T-cell lymphoma].
  • A 73-year-old woman was admitted with generalized lymphadenopathy, marked protrusion of the abdomen, severe systemic edema, oliguria, and dyspnea.
  • Histological examination of a cervical lymph node specimen showed a typical structure of angioimmunoblastic T-cell lymphoma.
  • CT scan revealed whole paraaortic lymphadenopathy, marked edematous lesions in the subcutaneous tissues and mesenterium, but small amounts of pleural effusion and ascites.
  • [MeSH-major] Edema / etiology. Immunoblastic Lymphadenopathy / blood. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell, Peripheral / blood. Lymphoma, T-Cell, Peripheral / complications. Vascular Endothelial Growth Factors / blood

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18080509.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


38. Tajika K, Tamai H, Mizuki T, Nakayama K, Yamaguchi H, Dan K: [Epstein-Barr virus-related B-cell lymphoma of the skin which developed early after cord blood transplantation for angioimmunoblastic T-cell lymphoma]. Rinsho Ketsueki; 2010 Feb;51(2):138-42
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epstein-Barr virus-related B-cell lymphoma of the skin which developed early after cord blood transplantation for angioimmunoblastic T-cell lymphoma].
  • We report here a rare case of EBV-related post-transplantation lymphoproliferative disorder (PTLD) localized to the skin.
  • The patient was a 64-year-old man diagnosed with angioimmunoblastic T cell lymphoma (AITL).
  • He underwent cord blood transplantation with a reduced intensity conditioning regimen during partial remission after chemotherapy.
  • Chimerism analysis revealed that the tumor cells were derived from donor cells, which led to the diagnosis of EBV-related PTLD.
  • [MeSH-major] Fetal Blood / transplantation. Herpesvirus 4, Human. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy. Lymphoproliferative Disorders / virology. Skin Diseases / virology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379106.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


39. Chang CJ, Cheng JH, Lin MS, Dai YC, Hsiue TR: Eosinophilic pleural effusion as the first presentation of angioimmunoblastic T cell lymphoma. J Formos Med Assoc; 2007 Feb;106(2):156-60
MedlinePlus Health Information. consumer health - Eosinophilic Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eosinophilic pleural effusion as the first presentation of angioimmunoblastic T cell lymphoma.
  • Eosinophilic pleural effusion (EPE), defined as pleural effusion that contains at least 10% eosinophils among the leukocytes, can be a manifestation of a great variety of diseases.
  • However, eosinophilia is a relatively rare finding in malignant pleural effusions, and it has been used as an indicator of good prognosis.
  • In clinical experience, very few cases of malignant lymphomas accompanied by EPE have been reported.
  • Pleural biopsy could not yield a definite diagnosis initially.
  • Six months later, bilateral neck, axillary and inguinal lymphadenopathy developed, and lymph node biopsy confirmed the diagnosis of angioimmunoblastic T cell lymphoma, with positive CD10 expression.
  • Therefore, we retrospectively carried out CD10 staining of the sample obtained from pleural biopsy and the positive result confirmed that the etiology of EPE was due to malignant T cell lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339160.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


40. Matsumiya H, Arai A, Nagai A: [A case of angioimmunoblastic T-cell lymphoma with interstitial shadow which disappeared after injection of hydrocortisone]. Nihon Kokyuki Gakkai Zasshi; 2006 Jul;44(7):537-40
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of angioimmunoblastic T-cell lymphoma with interstitial shadow which disappeared after injection of hydrocortisone].
  • A case of angioimmunoblastic T-cell lymphoma (AITL) was reported.
  • Her chest X-ray on admission showed mediastinal and bilateral hilar lymphademopathy (BHL) and interstitial shadows in both lower lung fields.
  • After intravenous injection of 200mg of hydrocortisone for 7 days, the interstitial shadows and BHL disappeared.
  • It was suspected that interstitial shadow was caused by pulmonary infiltration of AITL.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Hydrocortisone / administration & dosage. Immunoblastic Lymphadenopathy / drug therapy. Immunoblastic Lymphadenopathy / radiography. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886813.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


41. Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, Meijer CJ, Emile JF, Bouabdallah R, Bosly A, Diebold J, Haioun C, Coiffier B, Gisselbrecht C, Gaulard P, Groupe d'Etude des Lymphomes de l'Adulte: Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood; 2008 May 1;111(9):4463-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.
  • To evaluate the prognostic significance of clinicobiologic and pathological features in angioimmunoblastic T-cell lymphoma (AITL), 157 AITL patients were retrieved from the GELA LNH87-LNH93 randomized clinical trials.
  • In multivariate analysis, only male sex (P = .004), mediastinal lymphadenopathy (P = .041), and anemia (P = .042) adversely affected overall survival.
  • In conclusion, AITL is a morphologically heterogeneous T-cell lymphoma commonly expressing CXCL13 and CD10 and carrying few prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Chemokine CXCL13 / analysis. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunoblastic Lymphadenopathy. Middle Aged. Neprilysin / analysis. Prednisone / therapeutic use. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Analysis. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):218-24 [18182664.001]
  • [Cites] Nature. 2000 Jul 20;406(6793):309-14 [10917533.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Hematol J. 2001;2(4):279-85 [11920261.001]
  • [Cites] Hematol J. 2001;2(6):393-5 [11920279.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2472-9 [12011124.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2134-41 [12357368.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1272-8 [14607756.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4284-9 [12920037.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] N Engl J Med. 1975 Jan 2;292(1):1-8 [1078547.001]
  • [Cites] Cancer. 1978 Feb;41(2):578-606 [630540.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):318-21 [6861074.001]
  • [Cites] Cancer. 1987 Jan 15;59(2):208-12 [3802012.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):292-3 [2893097.001]
  • [Cites] Blood. 1988 Sep;72(3):1000-6 [3046680.001]
  • [Cites] Cancer. 1989 Apr 15;63(8):1625-9 [2924270.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1018-26 [2474057.001]
  • [Cites] Leukemia. 1991 Oct;5(10):892-5 [1961023.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Blood. 1993 Jul 1;82(1):241-6 [8391875.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Blood. 1996 Sep 15;88(6):2354-5 [8822958.001]
  • [Cites] Oncology. 1997 May-Jun;54(3):193-8 [9143398.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2945-53 [9256139.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):601-3 [9261530.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):643-55 [9630171.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Int J Hematol. 1998 Apr;67(3):319-29 [9650454.001]
  • [Cites] Leuk Lymphoma. 1999 Feb;32(5-6):545-52 [10048427.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1790-7 [15550584.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1197-205 [15788496.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1501-2 [16079436.001]
  • [Cites] Nat Rev Immunol. 2005 Nov;5(11):853-65 [16261173.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1101-7 [16680156.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1110-1 [16861359.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):787-92 [17228021.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1077-88 [17592275.001]
  • [Cites] Medicine (Baltimore). 2007 Sep;86(5):282-92 [17873758.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1309-15 [10715302.001]
  • (PMID = 18292286.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC2343588
  • [Investigator] Abdalsamad I; Dagger MF; Allard C; Angonin R; d'Anjou J; Audhuy B; Audouin J; Auzanneau G; Baglin AC; Bacilli C; Bastion Y; Baumelou E; Bensimon P; Berger F; Biron P; Blaise AM; Blanc M; Boman-Ferrand F; Boehn A; Boniver J; Bordes M; Bordessoule D; Bosly A; Bosq J; Bouabdallah R; Boucheron S; Bouvier J; Brice P; Brière J; Brousse N; Brousset P; Bryon PA; Caillot D; Carbillet JP; Casasnovas RO; Caulet T; Cazals D; Charlotte F; Charvillat L; Chesneau AM; Christian B; Coiffier B; Conroy T; Cordier JF; Cordonnier C; Clauvel JP; Deconinck E; Delage M; Delannoy A; Delmer A; Delos M; Delsol G; Devidas A; Diebold J; Diviné M; Dombret H; Doyen C; Duplay H; Dupriez B; Duval C; Eisenmann JC; Elbaz D; Emberger JM; Epardeau B; Fabiani B; Felman P; Fermand JP; Fermé C; Ferrand A; Ffrench M; Fievez M; Fillet G; Fonck Y; Froment N; Gabarre J; Galian P; Gasser O; Gaulard P; Gisselbrecht C; Gosselin B; Goutier C; Guy H; Guyotat D; Haioun C; Hamels J; Herbrecht R; Hopfner O; Horschowski N; Huguet F; Jacomy P; Jaubert J; Jeandel R; Kerneis Y; Knopf JP; Kuentz M; Labouyrie E; Lancien B; Laurent G; Lavergne A; Lavignac C; Leblond V; Lecomte-Houke M; Léderlin P; Lejeune F; Leger-Ravet MB; Loire R; Marcellin R; Marolleau JP; Marit G; Martin C; Marty-Double C; De Mascarel A; Méhaut S; Merlio JP; Merignargues C; Micléa JM; Michaux JL; Molina T; Monconduit M; Morel P; Morvan F; Mosnier JF; Nédellec G; Netter-Pinon C; Noel H; Nouvel C; Patey M; Peaud PY; Perie G; Peuchmaur M; Petrella T; Pignon B; Platini C; Pluot M; Pollet JP; Pujade-Lauraine E; Raphael M; Raymond-Gelle MC; Reiffers J; Reyes F; Rochet M; Rossi JF; Roucayrol AM; Rozenbaum A; Salles G; Schill H; Sebban C; Simon M; Solal-Céligny P; Straub P; Suc E; Sutton L; Symann M; Tertian G; Thiebaut S; Thyss A; Tilly H; Travade P; Trillet V; Vernant JP; Wendum D; Xerri L
  •  go-up   go-down


42. Tang XF, Li GD, Li YL, Liang DN, Xia T, Zhou JY, Yao YQ, Wu WQ, Wang ZG, Yang YH, Tang XB, Bai YQ, Ding Q: [Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified]. Zhonghua Bing Li Xue Za Zhi; 2009 Apr;38(4):224-30
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified].
  • OBJECTIVE: To study the value of immunomarkers CXCL13, CD10, bcl-6 in pathologic diagnosis of angioimmunoblastic T-cell lymphoma (AITL).
  • METHODS: One hundred and fifteen cases of AITL, 30 cases of peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) and 30 cases of reactive lymph nodes with paracortical hyperplasia (RH) encountered during the period from January, 1990 to January, 2008 were retrieved from the archival files of the Department of Pathology, West China Hospital of Sichuan University, China.
  • The morphologic features were reviewed and compared.
  • RESULTS: Regressed follicles were evident in 7.8% (9/115) of AITL cases, 6.7% (2/30) of PTCL, NOS cases and 83.3% (25/30) of RH cases, respectively.
  • A marked increase of number of arborizing venules was shown in 98.3% (113/115) of AITL cases, 63.3% (19/30) of PTCL, NOS cases and 76.7% (23/30) of RH cases, respectively.
  • In AITL, 96.5% (111/115) of cases showed CXCL13 expression, in contrast to 26.7% (8/30) of PTCL, NOS.
  • Expression of CD10 and bcl-6 were found in the neoplastic cells in 50.4% (58/115) and 78.3% (90/115) of AITL, and 3.3% (1/30) and 3.3% (1/30) of PTCL, NOS, respectively.
  • CONCLUSIONS: AITL is a type of lymphoma originated from the follicular helper T cells.
  • Detailed morphologic assessment and use of immunohistochemical markers are essential for accurate diagnosis.
  • [MeSH-major] Chemokine CXCL13 / metabolism. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neprilysin / metabolism. Proto-Oncogene Proteins c-bcl-6 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Pseudolymphoma / metabolism. Pseudolymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575892.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Proto-Oncogene Proteins c-bcl-6; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


43. Takahashi T, Maruyama R, Mishima S, Inoue M, Kawakami K, Onishi C, Miyake T, Tanaka J, Nabika T, Ishikura H: Small bowel perforation caused by Epstein-Barr virus-associated B cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. J Clin Exp Hematop; 2010;50(1):59-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel perforation caused by Epstein-Barr virus-associated B cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma.
  • On rare occasions, secondary Epstein-Barr virus (EBV)-associated B cell lymphoma can develop in a patient with angioimmunoblastic T-cell lymphoma (AITL).
  • We report a case of a 66-year-old Japanese woman who developed diffuse large B-cell lymphoma (DLBCL) in her small intestine after chemotherapy for AITL.
  • In situ hybridization for EBV-encoded RNA revealed positivity in the lymphoma cells.
  • The lymph nodes diagnosed as AITL were negative for EBV infection and there was no coexistence of B cell neoplasms in them.
  • We thought small bowel perforation in this case was caused by EBV-associated B cell lymphoma secondary to AITL.
  • Our case showed a remarkable deficiency of cellular immunity after chemotherapy, which we postulate was related to the cause of occurrence of B-cell lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Intestinal Neoplasms / complications. Intestinal Perforation / etiology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, T-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505277.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


44. Qin Y, Shi YK, He XH, Yang JL, Zhang CG, Zhou SY, Liu XF, Liu P, Yang S, Zhou LQ, Han XH, Yao JR: [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2010 Jun;32(6):448-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
  • OBJECTIVE: To retrospectively analyze the clinical features and prognostic factors of patients with angioimmunoblastic T-cell lymphoma (AITL).
  • All of the patients received CHOP-like regimens as initial chemotherapy, including 4 once treated with radiotherapy and 1 with high dose therapy followed by autologous stem cell transplantation (HDT-ASCT) as upfront consolidation therapy.
  • B-cell, T-cell and NK-cell subgroup proportions in the peripheral blood were tested by flow cytometry in 6 patients.
  • With the median follow-up of 26 months, the overall 2-year survival and disease free survival (DFS) rates were 62.2% and 44.4%, respectively.
  • In the univariate analysis, only age > 30 years and primary refractory disease adversely affected overall survival (OS); age > 30 years, advanced stage, B symptoms and splenomegaly adversely affected DFS.
  • Flow cytometry of peripheral blood lymphocytes showed that 5 of the 6 tested cases had decreasing proportion of CD3(+)CD4(+) T cells, B cells and NK cells but elevated CD3(+)CD8(+) T cells.
  • Two heavily treated patients achieved partial and complete response by thalidomide therapy, with a progression free survival (PFS) of 2 and 6+ months, respectively.
  • Peripheral blood lymphocytes test indicates that AITL patients suffered from both natural and acquired immune defects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunoblastic Lymphadenopathy / drug therapy. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adult. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Pneumonia / etiology. Prednisone / therapeutic use. Retrospective Studies. Stem Cell Transplantation. Survival Rate. Thalidomide / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20819488.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


45. Yu H, Shahsafaei A, Dorfman DM: Germinal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma. Am J Clin Pathol; 2009 Jan;131(1):33-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germinal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma.
  • Recently, we demonstrated that PD-1 is an immunophenotypic marker of GCTh cells and angioimmunoblastic T-cell lymphoma (AITL).
  • We studied 63 cases of T-cell lymphoproliferative disorders, including 22 cases of AITL.
  • In cases of AITL, PD-1+ and CXCL13+ neoplastic cells were seen at foci of expanded CD21+ follicular dendritic cell networks.
  • CXCL13 expression was limited in other peripheral T-cell lymphomas.
  • [MeSH-major] Antigens, CD / biosynthesis. Apoptosis Regulatory Proteins / biosynthesis. Chemokine CXCL13 / biosynthesis. Immunoblastic Lymphadenopathy / metabolism. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / metabolism
  • [MeSH-minor] Gene Expression Profiling. Humans. Programmed Cell Death 1 Receptor. Receptors, Complement 3d / analysis. T-Lymphocytes, Helper-Inducer / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095563.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / Receptors, Complement 3d
  •  go-up   go-down


46. Zhang D, Saunders CJ, Zhao W, Davis M, Cunningham MT: The clonality of CD3+ CD10+ T cells in angioimmunoblastic T cell lymphoma, B cell lymphoma, and reactive lymphoid hyperplasia. Am J Hematol; 2009 Sep;84(9):606-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clonality of CD3+ CD10+ T cells in angioimmunoblastic T cell lymphoma, B cell lymphoma, and reactive lymphoid hyperplasia.
  • T cells coexpressing CD3 and CD10 are a characteristic feature of angioimmunoblastic T-cell lymphoma (AITL) [1].
  • However, they are not unique to AITL, as these cells are also present in B cell lymphoma and reactive lymphoid hyperplasia [2].
  • To determine the significance of CD3+ CD10+ T cells, we used flow cytometry with cell sorting and molecular biology techniques for T cell gene rearrangement to study T cells from patients with AITL, B cell lymphoma, and reactive lymph node hyperplasia.
  • We found that CD3+ CD10+ T cells in B cell lymphoma and reactive lymphoid hyperplasia were polyclonal.
  • These findings illustrate the differences between early and late lymphoma and could be important for the diagnosis of AITL.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology. Pseudolymphoma / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Clone Cells. Humans. Immunoblastic Lymphadenopathy / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650143.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


47. Hagberg H, Pettersson M, Bjerner T, Enblad G: Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). Med Oncol; 2005;22(2):191-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4).
  • A patient with a CD4+ refractory peripheral T-cell lymphoma (PTL), subtype angioimmunoblastic T-cell lymphoma (AILD), was treated with a human monoclonal anti-CD4 antibody (HuMax-CD4) iv once weekly for 10 wk.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD4 / immunology. Immunoblastic Lymphadenopathy / therapy. Immunotherapy. Lymph Nodes / drug effects. Lymphoma, T-Cell, Peripheral / therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15965283.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD4
  •  go-up   go-down


48. Inoue D, Kimura T, Shimoji S, Mori M, Nagai Y, Tabata S, Kurata M, Matsushita A, Nagai K, Maruoka H, Yamashita E, Takahashi T: [Angioimmunoblastic T-cell lymphoma complicated by recurrent drug-induced agranulocytosis]. Rinsho Ketsueki; 2009 Feb;50(2):87-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma complicated by recurrent drug-induced agranulocytosis].
  • A 73-year-old man was hospitalized with fever, erythema, generalized superficial lymphadenopathy and marked neutropenia in July 2007.
  • Hematologic examination demonstrated a white blood cell count of 1,400/microl with 0% neutrophils, and 18% abnormal lymphocytes.
  • A diagnosis of drug-induced agranulocytosis was made.
  • Although neutrophil counts immediately returned to normal levels in response to filgrastim, fever, skin rash and systemic lymphadenopathy were all persistent.
  • Based on the histologic findings, PCR, and immunohistologic analyses, he was diagnosed with angioimmunoblastic T cell lymphoma (AILT) in leukemic state.
  • The response of the lymphoma to conventional chemotherapy (CHOP and ESHAP) was poor.
  • The treatment resulted in a partial remission of AILT including disappearance of circulating lymphoma cells.
  • To our knowledge, this is the first published report of AILT complicated by drug-induced agranulocytosis.
  • [MeSH-major] Acetaminophen / adverse effects. Agranulocytosis / chemically induced. Analgesics, Non-Narcotic / adverse effects. Immunoblastic Lymphadenopathy / etiology. Lymphoma, T-Cell / etiology

  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19265300.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 0 / Immunosuppressive Agents; 362O9ITL9D / Acetaminophen; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


49. Roncador G, García Verdes-Montenegro JF, Tedoldi S, Paterson JC, Klapper W, Ballabio E, Maestre L, Pileri S, Hansmann ML, Piris MA, Mason DY, Marafioti T: Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica; 2007 Aug;92(8):1059-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma.
  • BACKGROUND AND OBJECTIVES: In the present paper we report that SAP, an intracytoplasmic molecule that is involved in cell signaling, is an immunohistologic marker for germinal center T cells in paraffin-embedded tissue.
  • We document its expression, and also that of PD-1 (another recently described marker of germinal center T cells to which a new antibody has been raised), in normal and neoplastic lymphoid tissue to evaluate the suggestion that helper T cells within the germinal centers of human lymphoid tissue are the cell of origin of angioimmunoblastic T-cell lymphoma (AITL), and to assess the diagnostic value of these two markers.
  • DESIGN AND METHODS: Expression of SAP and PD-1 was investigated by immunohistochemistry in paraffin-embedded tissue sections and in cell lines.
  • Western blotting was performed on cell lines, and antibody specificity was confirmed by immunostaining of transfected cells.
  • RESULTS Screening on more than 500 lymphoma biopsies showed that 95% (40/42) of cases of AITL expressed at least one of these markers.
  • However, PD-1 and SAP were also found in a minority of cases of peripheral T-cell lymphoma other than AITL, in contrast to a report that the former marker is specific for AITL.
  • This observation raises the possibility that such non-angioimmunoblastic cases may be related to germinal center helper T cells.
  • They may also prove of value in the diagnosis of this disease since a negative reaction was rarely observed in this disorder.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Antigens, CD / analysis. Antigens, Differentiation, T-Lymphocyte / analysis. Apoptosis Regulatory Proteins / analysis. Germinal Center / pathology. Immunoblastic Lymphadenopathy / pathology. Intracellular Signaling Peptides and Proteins / analysis. Lymphoma, T-Cell / pathology. Neoplasm Proteins / analysis. T-Lymphocytes / chemistry
  • [MeSH-minor] Hodgkin Disease / metabolism. Hodgkin Disease / pathology. Humans. Lymphocytes, Tumor-Infiltrating / chemistry. Lymphocytes, Tumor-Infiltrating / pathology. Lymphoma, B-Cell / chemistry. Lymphoma, B-Cell / pathology. Palatine Tonsil / pathology. Programmed Cell Death 1 Receptor. Spleen / pathology. Thymus Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640856.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / SH2D1A protein, human
  •  go-up   go-down


50. Krivolapov IuA: [Histological and immunophenotypical characteristics of peripheral T-cell lymphomas]. Arkh Patol; 2005 Mar-Apr;67(2):17-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histological and immunophenotypical characteristics of peripheral T-cell lymphomas].
  • Histopathologic features of immunohistochemically confirmed 37 nodal peripheral T-cell lymphomas are described.
  • Unspecified and 10 angioimmunoblastic T-cell lymphomas were analyzed.
  • The most demonstrative histological features of both types of lymphomas were spectrum of small, medium and large lymphoid cells, lymphoid cells with irregular nuclei, presence of clusters of clear cells, arborizing endothelial venules, increased number of histiocytes, eosinophils and plasma cells.
  • Delineation between peripheral T-cell lymphoma, unspecified and angioimmunoblastic T-cell lymphoma needs evaluation of follicular dendritic cell pattern.
  • The results suggest that detection of histopathologic features typical for peripheral T-cell lymphomas gives an opportunity to compose optimal panel for immunotyping which is absolutely necessary.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / immunology. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938113.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


51. Yamamoto H, Miwa H, Kato Y, Nakamura S, Hara K, Nitta M: Angioimmunoblastic T cell lymphoma with an unusual proliferation of Epstein-Barr virus-associated large B cells arising in a patient with progressive systemic sclerosis. Acta Haematol; 2005;114(2):108-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T cell lymphoma with an unusual proliferation of Epstein-Barr virus-associated large B cells arising in a patient with progressive systemic sclerosis.
  • We report an unusual case of angioimmunoblastic T cell lymphoma arising in the setting of 5 years of immunosuppressive treatment for progressive systemic sclerosis.
  • Southern blot study demonstrated the clonal rearrangement of T cell receptor beta-chain gene, but not of immunoglobulin heavy chain gene.
  • Phenotypical examination of the lymph node also revealed the predominance of CD4+ T cells in addition to the proliferation of follicular dendritic cells, but no light chain restriction in large B cell components.
  • Based on the combined data described here, our preferred diagnosis was angioimmunoblastic T cell lymphoma with Epstein-Barr virus-associated B cell lymphoproliferative disorder, the pathogenesis of which was suggested to be closely associated with immunosuppressive treatment for progressive systemic sclerosis.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology. Scleroderma, Diffuse / pathology

  • Genetic Alliance. consumer health - Diffuse Scleroderma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16103635.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


52. de Leval L, Gisselbrecht C, Gaulard P: Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol; 2010 Mar;148(5):673-89

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the understanding and management of angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a distinct peripheral T-cell lymphoma (PTCL) entity with peculiar clinical and pathological features.
  • The recent identification of follicular helper T (T(FH)) cell as the cell of origin of this neoplasm represents a major step in our understanding of the pathobiological characteristics of the disease and should, in the future, clarify the diagnostic criteria for AITL and help to delineate its spectrum, especially from PTCL, not otherwise specified (PTCL, NOS).
  • Deciphering the pathogenesis of the disease is needed to identify targets for new therapies that are expected to improve the poor outcome of AITL patients, when treated with conventional chemotherapy regimens.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / physiopathology
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Cytogenetics. Diagnosis, Differential. Humans. Immunophenotyping. Prognosis. T-Lymphocytes, Helper-Inducer / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961485.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 170
  •  go-up   go-down


53. Bruneau J, Canioni D, Renand A, Marafioti T, Paterson JC, Martin-Garcia N, Gaulard P, Delfau MH, Hermine O, Macintyre E, Brousse N, Asnafi V: Regulatory T-cell depletion in angioimmunoblastic T-cell lymphoma. Am J Pathol; 2010 Aug;177(2):570-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory T-cell depletion in angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AITL) is the most frequent nodal T-cell lymphoma and is characterized by a polymorphic lymph node infiltrate, various dysimmune disorders, and a poor prognosis.
  • Regulatory T-cells (Treg) play an emerging role in the prognosis of non-Hodgkin B-cell lymphoma and mediate significant autoreactive T-cell suppression.
  • In this report, we demonstrate that numbers of Treg are significantly decreased in AITL lymph nodes [n = 30, 91 (40-195) per high power fields] compared with follicular lymphoma [n = 19, 179 (86-355)] and reactive lymph nodes [n = 8, 186 (140-265)].
  • Moreover, the few Treg in lymph nodes of AITL are resting Treg (rTreg) and have a naive CD45RA+, PD1-, and ICOS- phenotype [n = 5, 57% of Treg are CD45RA+ (16-96)], in contrast to the Treg in follicular lymphomas [n = 5, 7.4% (1-13)] or reactive lymph nodes [n = 7, 18.6% (6-48)].
  • Interestingly, Treg depletion was not observed in AITL peripheral blood at diagnosis.
  • [MeSH-major] Immunoblastic Lymphadenopathy / immunology. Lymphocyte Depletion. Lymphoma, T-Cell / immunology. T-Lymphocytes, Regulatory / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2006 Jul;36(7):1892-903 [16791882.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2957-64 [16825494.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Haematologica. 2008 Feb;93(2):193-200 [18223287.001]
  • [Cites] Blood. 2008 May 1;111(9):4463-70 [18292286.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1467-73 [15746048.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):2808-16 [16493037.001]
  • [Cites] Blood. 2006 May 1;107(9):3639-46 [16403912.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):802-10 [16819321.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1693-700 [16818676.001]
  • [Cites] Immunity. 2008 Jun;28(6):870-80 [18513999.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):682-90 [19295409.001]
  • [Cites] Immunity. 2009 Jun 19;30(6):899-911 [19464196.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1701-11 [16818678.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1101-7 [16680156.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1875-86 [14676299.001]
  • [Cites] J Clin Invest. 1987 Feb;79(2):637-42 [3805286.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] J Clin Pathol. 1998 Jul;51(7):506-11 [9797726.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5317-26 [10228007.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4051-61 [17371959.001]
  • (PMID = 20566750.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2913366
  •  go-up   go-down


54. Shah ZH, Harris S, Smith JL, Hodges E: Monoclonality and oligoclonality of T cell receptor beta gene in angioimmunoblastic T cell lymphoma. J Clin Pathol; 2009 Feb;62(2):177-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonality and oligoclonality of T cell receptor beta gene in angioimmunoblastic T cell lymphoma.
  • Angioimmunoblastic T cell lymphoma (AILT) is an aggressive T cell lymphoma with an incidence of approximately 1-2% of all non-Hodgkin lymphoma.
  • The detection of clonal T cell receptor (TCR) gene rearrangements helps in the diagnosis of T cell malignancies such as AILT, where morphological and immunohistological investigations are not always sufficient to reach a definitive diagnosis.
  • TCR beta (TCRB) and TCR gamma (TCRG) gene rearrangements were analysed from 17 WHO-defined cases of AILT by PCR for the presence of TCR clonality.
  • The results of this study emphasise that TCR clonality and oligoclonality is a diagnostic feature of AILT and that BV17S1 is over-represented with no other common molecular findings.
  • [MeSH-major] Immunoblastic Lymphadenopathy / genetics. Lymphoma, T-Cell / genetics. Receptors, Antigen, T-Cell, alpha-beta / genetics
  • [MeSH-minor] DNA, Neoplasm / genetics. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Neoplastic Stem Cells / pathology. Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18952689.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Receptors, Antigen, T-Cell, alpha-beta
  •  go-up   go-down


55. Bayerl MG, Hennessy J, Ehmann WC, Bagg A, Rosamilia L, Clarke LE: Multiple cutaneous monoclonal B-cell proliferations as harbingers of systemic angioimmunoblastic T-cell lymphoma. J Cutan Pathol; 2010 Jul;37(7):777-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple cutaneous monoclonal B-cell proliferations as harbingers of systemic angioimmunoblastic T-cell lymphoma.
  • We describe a 66-year-old man initially diagnosed with primary cutaneous marginal zone B-cell lymphoma who developed four additional monoclonal/monotypic B-cell lymphoid proliferations and a systemic angioimmunoblastic T-cell lymphoma over the course of 19 months.
  • Through retrospective analysis, we identified the evolution of a T-cell clone within the background of clinically and pathologically dominant cutaneous B-cell tumors.
  • In terms of clinical practice, this case supports that patients diagnosed with multiple clonal B-cell proliferation need thorough investigation and close clinical follow up to identify a coexistent or evolving systemic lymphoma, in particular, peripheral T-cell lymphomas of follicular T-helper cell type, such as angioimmunoblastic T-cell lymphoma.
  • Biologically, this case offers unique insight into the interactions between B-cell and T-cell lineages in lymphoid neoplasia.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Male. Polymerase Chain Reaction. Receptors, Antigen, T-Cell / genetics

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19702684.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


56. Tan BT, Warnke RA, Arber DA: The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn; 2006 Sep;8(4):466-75; quiz 527
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations.
  • We report on a series of 58 cases of angioimmunoblastic T-cell lymphoma (AILT) and 59 cases of peripheral T-cell lymphoma, unspecified (PTCL-NOS).
  • Subsets of cases from both diagnostic groups were complicated by associated B-cell proliferations, and we performed B- and T-cell clonality studies and in situ hybridization for Epstein-Barr virus (EBV) to investigate the relationship between B-cell proliferation, B-cell clonality, and EBV.
  • Using multiplex polymerase chain reaction assays based on the BIOMED-2 collaborative study, we detected TCRgamma T-cell clones in 78 and 81% of AILT and PTCL-NOS cases, respectively, and IGH B-cell clones in 34 and 35% of AILT and PTCL-NOS cases, respectively.
  • The majority of cases contained EBV-positive cells, including 50% of AILT and 57% of PTCL-NOS cases, and cases with B-cell proliferations were more often EBV-positive.
  • Although a relatively high rate of B-cell clonality has been shown for AILT, our findings for PTCL-NOS differ from previous reports in that B-cell clonality was relatively frequent.
  • Overall, a positive B-cell clone correlated, in part, with the presence of a B-cell proliferation but not with EBV.
  • Our findings demonstrate that B-cell clonality is a common finding in AILT and PTCL-NOS, and its presence should not negate the diagnosis established by morphologic, immunophenotypic, and clinical findings.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Herpesvirus 4, Human / genetics. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Cell Proliferation. Clone Cells. Female. Humans. Immunoglobulin Heavy Chains / genetics. Male. Middle Aged. Receptors, Antigen, T-Cell, gamma-delta / genetics

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2001 Nov;3(4):133-40 [11687596.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] J Mol Diagn. 2002 May;4(2):81-9 [11986398.001]
  • [Cites] J Pathol. 2002 Oct;198(2):171-80 [12237876.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2134-41 [12357368.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118(6):848-54 [12472277.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):117-21 [12691150.001]
  • [Cites] J Mol Diagn. 2003 May;5(2):82-7 [12707372.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):807-13 [12802918.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 1983 Jun;61(6):1138-45 [6404327.001]
  • [Cites] Blood. 1986 Jan;67(1):1-11 [3079640.001]
  • [Cites] Am J Clin Pathol. 1986 Apr;85(4):490-3 [2420169.001]
  • [Cites] Leukemia. 1987 Mar;1(3):235 [3669744.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Clin Chim Acta. 1991 Apr;198(1-2):93-174 [1863986.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Histopathology. 1993 Feb;22(2):145-9 [8384155.001]
  • [Cites] Blood. 1993 Jul 1;82(1):217-23 [8391874.001]
  • [Cites] Histopathology. 1994 Feb;24(2):115-22 [8181803.001]
  • [Cites] Blood. 1994 Jul 15;84(2):574-81 [8025283.001]
  • [Cites] Virchows Arch. 1994;424(6):593-600 [8055152.001]
  • [Cites] J Pathol. 1994 Dec;174(4):233-42 [7884584.001]
  • [Cites] Leuk Lymphoma. 1995 Sep;19(1-2):1-12 [8574154.001]
  • [Cites] J Clin Pathol. 1995 Nov;48(11):1045-50 [8543629.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):956-64 [9706975.001]
  • [Cites] J Pathol. 1998 May;185(1):79-85 [9713363.001]
  • [Cites] Mol Diagn. 1999 Jun;4(2):119-33 [10462627.001]
  • [Cites] Hematol Oncol. 2004 Dec;22(4):169-77 [16134192.001]
  • [Cites] J Mol Diagn. 2005 Oct;7(4):495-503 [16237219.001]
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1269-79 [11144922.001]
  • [Cites] Diagn Mol Pathol. 2001 Jun;10(2):69-77 [11385314.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [CommentIn] J Mol Diagn. 2006 Sep;8(4):426-9; quiz 526-7 [16931581.001]
  • (PMID = 16931587.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Other-IDs] NLM/ PMC1867616
  •  go-up   go-down


57. de Leval L, Rickman DS, Thielen C, Reynies Ad, Huang YL, Delsol G, Lamant L, Leroy K, Brière J, Molina T, Berger F, Gisselbrecht C, Xerri L, Gaulard P: The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood; 2007 Jun 1;109(11):4952-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.
  • The molecular alterations underlying the pathogenesis of angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma, unspecified (PTCL-u) are largely unknown.
  • The molecular profile of AITLs was characterized by a strong microenvironment imprint (overexpression of B-cell- and follicular dendritic cell-related genes, chemokines, and genes related to extracellular matrix and vascular biology), and overexpression of several genes characteristic of normal follicular helper T (T(FH)) cells (CXCL13, BCL6, PDCD1, CD40L, NFATC1).
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Lymphoma, T-Cell, Peripheral / immunology. Lymphoma, T-Cell, Peripheral / metabolism


58. Kawano R, Ohshima K, Wakamatsu S, Suzumiya J, Kikuchi M, Tamura K: Epstein-Barr virus genome level, T-cell clonality and the prognosis of angioimmunoblastic T-cell lymphoma. Haematologica; 2005 Sep;90(9):1192-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus genome level, T-cell clonality and the prognosis of angioimmunoblastic T-cell lymphoma.
  • BACKGROUND AND OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AILT) is a peripheral T-cell tumor of unknown etiology with variable biological and clinical presentations.
  • Previous clonality studies have shown heterogeneous clonal restrictions of B- and T-cell populations in this tumor.
  • AILT is characterized by the presence of increased numbers of Epstein-Barr virus (EBV) infected cells.
  • DESIGN AND METHODS: Frozen material from 59 cases of AILT was used for DNA isolation and gene analysis by Southern blotting.
  • Survival rate did not correlate with either T-cell clonality (p=0.84), or presence of EBV-infected cells (p=0.84).
  • The EBV-DNA copy number in EBV-infected tissue did not correlate with disease progression (p=0.87).
  • The survival rate and clinical status according to the international prognostic index (IPI) did not correlate with T-cell clonality status or EBV infection.
  • INTERPRETATION AND CONCLUSIONS: AILT remains a heterogeneous disease with clinical behavior that varies irrespective of the genomic parameters investigated.
  • [MeSH-major] Genome, Viral. Herpesvirus 4, Human / genetics. Immunoblastic Lymphadenopathy / genetics. Immunoblastic Lymphadenopathy / virology. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / virology. T-Lymphocytes / immunology. T-Lymphocytes / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16154842.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


59. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ, Novitzky N, Goldstone AH, Sureda A, Schmitz N: Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol; 2009 Aug 20;27(24):3951-8
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.
  • PURPOSE: To analyze the long-term outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), progression-free survival (PFS), and overall survival (OS) in patients with angioimmunoblastic T-cell lymphoma (AITL) treated with allogeneic stem-cell transplantation (alloSCT).
  • Median age was 48 years (range, 23 to 68 years), 34 patients had received > or = two lines of chemotherapy before alloSCT, and 11 patients had experienced treatment failure with a prior autologous stem-cell transplantation.
  • Twenty-seven patients were allografted in chemotherapy-sensitive disease, and 18 were allografted in refractory disease.
  • RR was estimated as 16% and 20% at 2 and 3 years, respectively, and was lower in patients developing chronic graft-versus-host disease (cGVHD).
  • Both the lower RR after transplantation as well as the decreased RR in patients developing cGVHD after the alloSCT suggests the existence of a clinically relevant graft-versus-lymphoma effect.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adult. Aged. Female. Graft vs Host Disease / epidemiology. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620487.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Konstantinou K, Yamamoto K, Ishibashi F, Mizoguchi Y, Kurata M, Nakagawa Y, Suzuki K, Sawabe M, Ohta M, Miyakoshi S, Crawley JT, Kitagawa M: Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma. Br J Haematol; 2009 Mar;144(5):696-704
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AILT) is a malignant disease of peripheral T-cell origin that is characterized by a prominent proliferation of high endothelial venules in the lymph node.
  • To investigate angiogenic mechanisms in AILT we measured the angiogenic mediator gene expression levels in the lymph nodes of 54 non-Hodgkin lymphoma patients, by immunostaining and quantitative reverse transcription polymerase chain reaction.
  • Angiogenic mediators angiopoietin (Ang) 1 (ANGPT1), Ang2 (ANGPT2) and their receptor, Tie2 (TEK), vascular endothelial growth factor (VEGF; VEGFA) and its receptor, VEGFR2 (KDR), and hepatocyte growth factor (HGF) and its receptor, c-Met (MET) were all more highly expressed in AILT lymph nodes (16 cases) than in B-cell lymphomas (24 cases).
  • Moreover, significantly higher Ang1 and Tie2 expression was detected in AILT cases with CD10-positive neoplastic T-cells by comparison with unspecified peripheral T-cell lymphoma (14 cases).
  • These results suggest that the angiopoietin system may play an important role in the development of high vascularity in AILT lymph nodes.
  • Consequently, as neoplastic T-cells and follicular dendritic cells are both increased in AILT and may represent an important source of angiogenic mediators, targeting these cells with anti-angiogenic strategies might represent a novel therapy for AILT.
  • [MeSH-major] Angiopoietins / metabolism. Lymph Nodes / metabolism. Lymphoma, T-Cell, Peripheral / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19120365.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / Angiopoietins; 0 / Antigens, CD3; 0 / Biomarkers, Tumor; 0 / Receptors, Complement 3d; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, TIE-2; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


61. Lachenal F, Berger F, Ghesquières H, Biron P, Hot A, Callet-Bauchu E, Chassagne C, Coiffier B, Durieu I, Rousset H, Salles G: Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients. Medicine (Baltimore); 2007 Sep;86(5):282-92
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients.
  • We retrospectively analyzed 77 patients with pathologically diagnosed angioimmunoblastic T-cell lymphoma from a single city.
  • Average time between first symptoms of the disease and diagnosis was 3.6 months.
  • At diagnosis, peripheral nodes were present in all but 1 patient, and were generalized in 90% of cases.
  • Other clinical manifestations included pleuritis (22%); arthralgia or arthritis (17%); ear, nose, and throat involvement (14%); central or peripheral neurologic manifestations (10%); and ascites (5%).
  • Most patients presented with advanced disease at diagnosis (bone marrow involvement in 60% of cases).
  • Auto- or disimmune manifestations were reported in one-third of patients: autoimmune hemolytic anemia was present at diagnosis in 19% of patients and thrombocytopenic purpura in 7%.
  • Clonality was analyzed in lymph nodes in 47 patients: T-cell and B-cell clones were found in 45 (96%) and 20 (45%) patients, respectively.
  • The current study underlines the diversity of presenting manifestations of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Cytological Techniques. Diagnostic Errors. Disease Progression. Female. Follow-Up Studies. Herpesvirus 4, Human / isolation & purification. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Viral / analysis. Retrospective Studies. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17873758.001).
  • [ISSN] 0025-7974
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / RNA, Viral
  •  go-up   go-down


62. Carbone A, Gloghini A, Cabras A, Elia G: The Germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol; 2009 May;145(4):468-80
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Germinal centre-derived lymphomas seen through their cellular microenvironment.
  • The human lymph node is a complex tissue resulting from the microenvironmental organisation of different cell populations linked by topographical and/or functional relationships.
  • On the whole, GC exerts a role in B cell physiology and malignancy.
  • In GC-derived lymphomas, gene expression profiling studies have raised the possibility that survival of the affected patients may be associated with signatures preferentially expressed in non-malignant T cells and macrophages and/or dendritic cells.
  • Immunohistological analyses in lymphoma biopsy samples have confirmed that the biological behaviour and tumour progression may be influenced by the tumour microenvironment.
  • This review will examine GC-derived lymphomas, including follicular lymphomas, Hodgkin lymphomas and angioimmunoblastic T-cell lymphoma, through their integrated cellular microenvironment, highlighting those findings which may serve as a useful surrogate marker for tumour diagnosis or tumour progression, together with key molecules involved in tumour development.
  • [MeSH-major] B-Lymphocytes / immunology. Gene Expression Regulation, Neoplastic. Germinal Center / physiology. Hodgkin Disease / immunology. Lymphoma, Follicular / immunology. Lymphoma, T-Cell / immunology
  • [MeSH-minor] Disease Progression. Humans. Immunohistochemistry. T-Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19344401.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 83
  •  go-up   go-down


63. Jayaraman AG, Cassarino D, Advani R, Kim YH, Tsai E, Kohler S: Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology. J Cutan Pathol; 2006 Sep;33 Suppl 2:6-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology.
  • Angioimmunoblastic T-cell lymphoma (AILT) is an aggressive peripheral T-cell lymphoma that is frequently accompanied by a cutaneous eruption.
  • Here, we review the previously reported histologic patterns and present a case of AILT involving the skin with a unique histologic appearance of necrotizing granulomas with abundant histiocytes and eosinophils, mimicking an infectious etiology.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Skin Diseases, Infectious / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Lymph Nodes / pathology. Male. Middle Aged


64. Yuan X, Chen F, Bi D, Zhao X, He Q, Li Q: [Clinicopathologic features and diagnosis of 18 patients with angioimmunoblastic T-cell lymphoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jun;34(6):523-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features and diagnosis of 18 patients with angioimmunoblastic T-cell lymphoma].
  • OBJECTIVE: To explore the clinical and pathologic features of angioimmunoblastic T-cell lymphoma(AITL) and provide evidence for diagnosis.
  • RESULTS: Characteristic features at the presentation of AITL included generalized lymphadenopathy, fever, splenomegaly, and skin rashes with polyclonal hyper-gammaglobulinemia and other hematological abnormalities (such as Coombs-positive hemolytic anemia), which often involved the bone marrow and had well-described histologic features.
  • CONCLUSION: Repeated lymphadenbiopsy is helpful for AITL diagnosis.
  • Routine histological and immunohistochemical examinations (especially including CXCL13) play significant role in the diagnosis and differential diagnosis of AITL.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19587435.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13
  •  go-up   go-down


65. Ramasamy K, Lim Z, Pagliuca A, Salisbury JR, Mufti GJ, Devereux S: Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. Haematologica; 2006 Aug;91(8 Suppl):ECR44
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone.
  • Angioimmunoblastic T cell lymphoma (AITL) is a peripheral T-cell lymphoma characterized morphologically by lymphadenopathy with a polymorphic infiltrate, marked vascular and follicular dendritic cell proliferation.
  • Patients usually present with advanced disease and the overall prognosis is poor.
  • [MeSH-major] Dexamethasone / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy. Thalidomide / therapeutic use

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923528.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


66. Advani R, Horwitz S, Zelenetz A, Horning SJ: Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma; 2007 Mar;48(3):521-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine.
  • Angioimmunoblastic T cell lymphoma is a distinct entity for which there is no standard therapy.
  • On the basis of the rationale that CsA may represent a novel drug for AITL, a disease with considerable immune dysregulation, and encouraging case reports, the authors have treated 12 patients with this agent.
  • Responding patients received a maintenance dose of 50 - 100 mg, with a gradual taper after a maximal response was achieved as tolerated.
  • By interrupting T-cell activation, CsA may alter the immune dysregulation that characterizes AILT.
  • The efficacy of CsA is being explored in patients with recurrent AILT in a prospective trial (ECOG 2402).
  • [MeSH-major] Cyclosporine / therapeutic use. Immunoblastic Lymphadenopathy / drug therapy. Immunosuppressive Agents / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Mar;48(3):449-51 [17454581.001]
  • (PMID = 17454592.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


67. Imafuku S, Yoshimura D, Moroi Y, Urabe K, Furue M: Systemic varicella zoster virus reinfection in a case of angioimmunoblastic T-cell lymphoma. J Dermatol; 2007 Jun;34(6):387-9
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic varicella zoster virus reinfection in a case of angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that causes immunological disorders such as immunosuppression, autoimmune disease-like symptoms and allergy.
  • [MeSH-major] Chickenpox / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Acyclovir / administration & dosage. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antiviral Agents / administration & dosage. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Herpesvirus 3, Human / immunology. Humans. Immunocompromised Host. Infusions, Intravenous. Male. Prednisone / administration & dosage. Recurrence. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Chickenpox.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535405.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiviral Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; D58G680W0G / pirarubicin; VB0R961HZT / Prednisone; X4HES1O11F / Acyclovir
  •  go-up   go-down


68. Alizadeh AA, Advani RH: Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clin Adv Hematol Oncol; 2008 Dec;6(12):899-909
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare and complex lymphoproliferative disorder, clinically characterized by widespread lymphadenopathy, extranodal disease, immune-mediated hemolysis, and polyclonal hypergammaglobulinemia.
  • Significant progress has been made in the understanding of AITL since its recognition as a clonal T-cell disorder with associated deregulation of B-cells and endothelial cells within a unique malignant microenvironment.
  • We discuss recent developments in the understanding of the pathogenesis of AITL at a cellular and molecular level, including the implication of the follicular helper T-cell as the corresponding cell of origin, the roles of Epstein-Barr virus, B-cell deregulation, angiogenesis, and other signaling pathways in AITL, and the therapeutic implications of these findings.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19209140.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 2S9ZZM9Q9V / Bevacizumab; 4F4X42SYQ6 / Rituximab; 83HN0GTJ6D / Cyclosporine
  • [Number-of-references] 100
  •  go-up   go-down


69. Lafaras C, Mandala E, Venizelos I, Valeri R, Barbetakis N, Bischiniotis T: Cardiac tamponade as primary manifestation of angioimmunoblastic T-cell lymphoma (AILT). Coexistence with malignant mesothelioma. Onkologie; 2008 Oct;31(10):546-8
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac tamponade as primary manifestation of angioimmunoblastic T-cell lymphoma (AILT). Coexistence with malignant mesothelioma.
  • BACKGROUND: Cardiac tamponade (CT) as the primary clinical manifestation of lymphomas is extremely rare.
  • Angioimmunoblastic T-cell lymphoma (AILT) is characterised by systemic disease usually presenting with generalised peripheral lymphadenopathy, hepatosplenomegaly, and bone marrow infiltration.
  • CASE REPORT: We report on a 59-year-old male patient with CT as initial clinical manifestation of AILT.
  • Coexistence with malignant pleural mesothelioma was additionally revealed.
  • Cytologic examination of pericardial fluid presented diffuse lymphoid cells and sporadic malignant mesothelial cells.
  • AILT diagnosis was confirmed by thoracoscopic mediastinal lymph node and bone marrow biopsy.
  • Despite the presence of pleural effusion, the diagnosis of mesothelioma was initially established by cytologic ex-amination of pericardial fluid, due to the patient's critical cardiac condition requiring prompt subxiphoid pericardiocentesis.
  • CONCLUSION: CT as primary clinical manifestation of AILT is very rare.
  • This case reflects the differences in the underlying biology of AILT and consequently the vast spectrum of its clinical presentations.
  • Coexistence of AILT with malignant pleural mesothelioma is also extremely rare.
  • [MeSH-major] Cardiac Tamponade / diagnosis. Cardiac Tamponade / etiology. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma / complications. Lymphoma / diagnosis. Mesothelioma / complications. Mesothelioma / diagnosis


70. Omura H, Nagata N, Wakamatsu K, Minami T, Taguchi K, Okamura K, Ono S, Katahira K, Maki S, Akasaki T: [Case of angioimmunoblastic T-cell lymphoma with eosinophilia and interstitial shadows]. Nihon Kokyuki Gakkai Zasshi; 2010 Nov;48(11):831-5
MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of angioimmunoblastic T-cell lymphoma with eosinophilia and interstitial shadows].
  • A 76-year-old woman was admitted because of respiratory failure with bilateral multiple interstitial shadows and mediastinal adenopathy on chest CT images.
  • Corticosteroids were administered before diagnosis because of rapid respiratory failure.
  • A definitive diagnosis was not obtained until bronchofiberoptic examination.
  • At the time of recurrence 6 months later, angioimmunoblastic T-cell lymphoma (AITL) was diagnosed with axillary lymph node biopsy.
  • Lymph node biopsy is necessary to establish a definitive diagnosis.
  • [MeSH-major] Eosinophilia / complications. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / diagnosis. Lung Diseases, Interstitial / complications
  • [MeSH-minor] Aged. Axilla. Biopsy. Diagnosis, Differential. Female. Humans. Lymph Nodes / pathology. Mediastinum. Radiography, Thoracic. Respiratory Insufficiency / etiology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21141062.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


71. Cho YU, Chi HS, Park CJ, Jang S, Seo EJ, Huh J: Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement. Am J Clin Pathol; 2009 May;131(5):640-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement.
  • We retrospectively reviewed the clinical and laboratory data and bone marrow (BM) histomorphologic features in 33 angioimmunoblastic T-cell lymphoma (AITL) cases.
  • Paraffin-embedded BM core biopsy specimens were reacted immunohistochemically with antibodies to pan-T-cell markers, CD20, CD10, CD21, and bcl-6.
  • Morphologic features included nodular or interstitial infiltration in a paratrabecular distribution, periodic acid-Schiff-positive intercellular materials, mixed infiltrates of T and B cells, presence of clear cells, and blood vessel proliferation.
  • Seven cases with BM involvement were interpreted as negative for lymphoma initially, mainly owing to insufficient information in nodal biopsy specimens.
  • Several clinical and laboratory features indicate BM involvement of AITL at diagnosis.
  • [MeSH-major] Bone Marrow / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369622.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


72. Munemasa S, Sakai A, Sasaki N, Okikawa Y, Mihara K, Kimura A: [Angioimmunoblastic T-cell lymphoma complicated with EBV-associated B-cell lymphoma]. Rinsho Ketsueki; 2005 Feb;46(2):127-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma complicated with EBV-associated B-cell lymphoma].
  • The immunohistochemical and pathologic findings from the biopsy specimens led to the diagnosis of angioimmunoblastic T-cell lymphoma (AILT) with a cluster of CD20-positive cells.
  • These findings indicated a diagnosis of angioimmunoblastic T-cell lymphoma complicated with EBV-associated B-cell lymphoma, and that immunodeficiency in AILT led to an expansion of EBV infected B-cells.
  • [MeSH-major] Epstein-Barr Virus Infections. Immunoblastic Lymphadenopathy / complications. Lymphoma, B-Cell / etiology
  • [MeSH-minor] Aged. Gene Rearrangement. Humans. Immunocompromised Host. Immunoglobulin Heavy Chains / genetics. Male. Molecular Diagnostic Techniques. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447706.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


73. Dunleavy K, Wilson WH, Jaffe ES: Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. Curr Opin Hematol; 2007 Jul;14(4):348-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications.
  • PURPOSE OF REVIEW: Angioimmunoblastic T cell lymphoma is a complex lymphoproliferative disorder.
  • While recent evidence suggests that the Epstein-Barr virus and B cell disregulation are implicated in the disease's pathogenesis, their mechanistic roles remain largely unknown.
  • The prognosis with traditional chemotherapy has been poor, but improved understanding of the disease's pathobiology has led to several promising novel therapeutic strategies.
  • RECENT FINDINGS: The recent finding of overexpression of the chemokine CXCL13 by the neoplastic cells of angioimmunoblastic T cell lymphoma suggests that it is derived from follicular helper T cells.
  • Novel therapeutic strategies including immunomodulation with agents like cyclosporine and angiogenesis inhibition with drugs such as bevacizumab are being investigated, and show early promise in this disease.
  • SUMMARY: Diseases such as angioimmunoblastic T cell lymphoma can help illuminate the biology of the normal immune system.
  • Significant progress has been made in understanding the biology of angioimmunoblastic T cell lymphoma.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / etiology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Herpesvirus 4, Human. Humans. Immunoblastic Lymphadenopathy. Vascular Endothelial Growth Factor A

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534160.001).
  • [ISSN] 1065-6251
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 48
  •  go-up   go-down


74. Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, Hashikawa K, Kiyasu J, Takeuchi M, Suefuji N, Sugita Y, Takeya M, Ohshima K: Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int; 2010 Apr;60(4):278-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL).
  • Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma characterized by systemic disease with polymorphous infiltrate including macrophages.
  • Although many studies of tumor-associated macrophage (TAM) populations in various malignant tumors have been published, only a few have dealt with activation of macrophage phenotypes such as M1 and M2 in tumor tissue.
  • [MeSH-major] Antigens, Differentiation, Myelomonocytic / immunology. Lymphoma, T-Cell, Peripheral / immunology. Lymphoma, T-Cell, Peripheral / mortality. Macrophages / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunoblastic Lymphadenopathy / immunology. Immunoblastic Lymphadenopathy / pathology. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Severity of Illness Index. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403029.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Differentiation, Myelomonocytic
  •  go-up   go-down


75. Nakashima M, Suzuki K, Okada M, Takada K, Kobayashi H, Hama Y: Successful coil embolization of a ruptured hepatic aneurysm in a patient with polyarteritis nodosa accompanied by angioimmunoblastic T cell lymphoma. Clin Rheumatol; 2007 Aug;26(8):1362-4
Genetic Alliance. consumer health - Polyarteritis nodosa.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful coil embolization of a ruptured hepatic aneurysm in a patient with polyarteritis nodosa accompanied by angioimmunoblastic T cell lymphoma.
  • Polyarteritis nodosa (PN) occasionally develops in association with malignant disorders.
  • A biopsy of the right inguinal lymph node demonstrated angioimmunoblastic T cell lymphoma (AITL).
  • [MeSH-major] Aneurysm, Ruptured / therapy. Embolization, Therapeutic. Hepatic Artery / pathology. Immunoblastic Lymphadenopathy / complications. Polyarteritis Nodosa / complications
  • [MeSH-minor] Aged. Humans. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17106619.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


76. Khaled A, Sfia M, Fazaa B, Kourda N, Zermani R, Baccouche K, Ben Jilani S, Kamoun MR: [Chronic prurigo revealing an angioimmunoblastic T cell lymphoma]. Tunis Med; 2009 Aug;87(8):534-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic prurigo revealing an angioimmunoblastic T cell lymphoma].
  • [Transliterated title] Prurigo chronique révélant un lymphome T angio- immunoblastique.
  • BACKGROUND: Cutaneous manifestations in angio-immunoblastic T cell lymphoma (AITL) can be seen in almost 50% of patients.
  • Immunohistochemical study showed T cell phenotype (CD3+).
  • Molecular biological analysis of a lymph node showed a T cell clonal proliferation.
  • The diagnosis of angio-immunoblastic T cell lymphoma was made.
  • CONCLUSION: In front of chronic prurigo with general manifestations, a careful etiologic screening should be done to detect internal disorders especially malignant hemopathies.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell / diagnosis. Paraneoplastic Syndromes / diagnosis. Prurigo / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20180359.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


77. Togashi M, Wakui H, Kodama K, Kameoka Y, Komatsuda A, Nimura T, Ichinohasama R, Sawada K: Angioimmunoblastic T-cell lymphoma and membranous nephropathy: a still unreported association. Clin Exp Nephrol; 2010 Jun;14(3):288-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma and membranous nephropathy: a still unreported association.
  • A 21-year-old man with lymphadenopathy and Coombs-positive hemolytic anemia had been treated with steroid maintenance therapy.
  • He developed nephrotic syndrome with size increase of lymphadenopathy.
  • Lymph node examination disclosed angioimmunoblastic T-cell lymphoma (AITL).
  • [MeSH-major] Glomerulonephritis, Membranous / complications. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / diagnosis. Nephrotic Syndrome / etiology

  • Genetic Alliance. consumer health - Membranous nephropathy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20177729.001).
  • [ISSN] 1437-7799
  • [Journal-full-title] Clinical and experimental nephrology
  • [ISO-abbreviation] Clin. Exp. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


78. Willenbrock K, Renné C, Gaulard P, Hansmann ML: In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study. Virchows Arch; 2005 Jan;446(1):15-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study.
  • The significance of T-cell proliferations in angioimmunoblastic lymphoma (AILD) is still enigmatic.
  • Although classified as a malignant T-cell lymphoma in the World Health Organisation lymphoma classification, some cases of AILD lack dominant T-cell clones.
  • In a previous study, based on single-cell polymerase chain reaction (PCR), we obtained similar results as studies of AILD using Southern blot or conventional PCR: some cases of AILD contained large T-cell clones, and, in other cases, T-cell clones were undetectable.
  • As in single-cell studies, only a limited number of cells could be investigated; thus, we wanted to gain more insight into the amount and distribution of tumour cells.
  • By applying triple immunofluorescent staining with antibodies directed against T-cell receptor Vbeta-family-specific epitopes, we investigated T-cell populations in AILD and their localisation in the tissue in relation to B cells (CD20) and follicular dendritic cells (CD21).
  • [MeSH-major] Immunoblastic Lymphadenopathy / immunology. Lymphoma, T-Cell / immunology. T-Lymphocytes / pathology
  • [MeSH-minor] Antigens, CD20 / analysis. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Polymerase Chain Reaction. Receptors, Antigen, T-Cell, alpha-beta / analysis. Receptors, Complement 3d / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15480765.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Complement 3d
  •  go-up   go-down


79. Attygalle AD, Kyriakou C, Dupuis J, Grogg KL, Diss TC, Wotherspoon AC, Chuang SS, Cabeçadas J, Isaacson PG, Du MQ, Gaulard P, Dogan A: Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol; 2007 Jul;31(7):1077-88

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression.
  • Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon, but aggressive nodal peripheral T-cell lymphoma.
  • Eleven cases where polymerase chain reaction results for T-cell receptor-gamma gene rearrangement were directly compared showed an identical band-size in the initial and follow-up biopsies.
  • Seven cases (23%) developed EBV-associated B-cell lymphomas [5 diffuse large B-cell lymphoma (DLBCL) and 2 classic Hodgkin lymphoma].
  • In 4 cases, a dominant B-cell clone was observed in biopsies lacking evidence of DLBCL.
  • A single case was complicated by EBV-negative DLBCL, whereas another with large cell transformation had a T-cell phenotype.
  • In conclusion, AITL represents a clonal T-cell proliferation with a stable T-cell clone throughout the disease.
  • When "morphologic high-grade transformation" occurs, it is usually due to a secondary (often EBV-associated) B-cell lymphoma, rather than a T-cell neoplasm.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, T-Cell, Peripheral / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Biopsy. Clone Cells / metabolism. Clone Cells / pathology. Disease Progression. Disease-Free Survival. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / pathology. Female. Gene Rearrangement, T-Lymphocyte. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization. Male. Middle Aged. Neoplasm Staging. RNA, Viral / analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592275.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Viral
  •  go-up   go-down


80. Chuang SS, Ichinohasama R, Chu JS, Ohshima K: Differential diagnosis of angioimmunoblastic T-cell lymphoma with seropositivity for anti-HTLV antibody from adult T-cell leukemia/lymphoma. Int J Hematol; 2010 May;91(4):687-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of angioimmunoblastic T-cell lymphoma with seropositivity for anti-HTLV antibody from adult T-cell leukemia/lymphoma.
  • Angioimmunoblastic lymphoma (AITL) is a nodal peripheral T-cell lymphoma characterized by a proliferation of arborizing vessels and hyperplastic follicular dendritic cells as well as a polymorphous lymphoid infiltrate including neoplastic cells with clear cytoplasm.
  • Adult T-cell leukemia/lymphoma (ATLL) is caused by the retrovirus human T-cell leukemia virus type I (HTLV-I), and the neoplastic cells are usually large and pleomorphic.
  • Recently, a rare morphologic variant of ATLL with AITL-like features has been reported.
  • Here, we presented a case of peripheral T-cell lymphoma with morphological features of AITL in Taiwan, a country non-endemic for HTLV, and the patient was seropositive for anti-HTLV antibody, which raised the possibility of ATLL with AITL-like features.
  • Our investigations indicated that in an HTLV-I non-endemic area, a peripheral T-cell lymphoma with typical morphologic and immunophenotypic features of AITL could be confidently diagnosed as AITL even if the patient was seropositive for anti-HTLV antibody.
  • [MeSH-major] HTLV-I Antibodies / blood. HTLV-I Infections / complications. HTLV-I Infections / immunology. Immunoblastic Lymphadenopathy. Lymphoma, T-Cell
  • [MeSH-minor] Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Humans. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198459.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HTLV-I Antibodies
  •  go-up   go-down


81. Laforga JB, Gasent JM, Vaquero M: Potential misdiagnosis of angioimmunoblastic T-cell lymphoma with Hodgkin's lymphoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):840-4
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential misdiagnosis of angioimmunoblastic T-cell lymphoma with Hodgkin's lymphoma: a case report.
  • BACKGROUND: Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive neoplasm.
  • We investigated the potential utility of touch imprints evaluated in conjunction with the histology of lymph nodes in the diagnosis of AITL.
  • CASE A 58-year-old man presented with generalized lymphadenopathy, splenomegaly, and autoimmune phenomena, which complicated the diagnosis.
  • Touch imprints were obtained from the lymph node biopsy, which were valuable in making the correct diagnosis.
  • CONCLUSION: We draw attention to this neoplastic diagnosis and correlate the cytomorphologic and immunohistochemical findings with the adequate clinical setting in order to avoid misdiagnosis, primarily with Hodgkin's lymphoma and reactive hyperplasia.
  • Touch imprints are useful in the diagnosis of AITL if the broad population of proliferating cells is distinguished.
  • However, some cases display binucleated or mononucleated cells with prominent nucleoli and many eosinophils, which may induce a potential misdiagnosis with Hodgkin's lymphoma.
  • [MeSH-major] Diagnostic Errors. Hodgkin Disease / diagnosis. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053552.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Argov O, Charach G, Weintraub M, Shtabsky A: Angioimmunoblastic T-cell lymphoma presenting as giant kidneys: a case report. J Med Case Rep; 2009;3:9258

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma presenting as giant kidneys: a case report.
  • INTRODUCTION: Angioimmunoblastic T-cell lymphoma is a rare form of tumor of the lymph nodes or lymphoid tissue.
  • In this report we describe an unusual presentation of angioimmunoblastic T-cell lymphoma consisting of giant kidneys with no nephrotic syndrome.
  • The results of the physical examination and laboratory tests raised the possibility of neoplastic disease.
  • The genetic examination revealed T-cell lymphoma.
  • Diagnosis was made by a lymph node biopsy, which shows typical findings of angioimmunoblastic T-cell lymphoma.
  • CONCLUSIONS: Angioimmunoblastic T-cell lymphoma can present with huge kidneys without nephrotic syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1992 Sep 1;117(5):364-70 [1380221.001]
  • [Cites] Ann Hematol. 2004 Nov;83(11):731-2 [15309529.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):455-9 [15034757.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Lancet. 1974 Jun 1;1(7866):1070-3 [4135245.001]
  • (PMID = 19918294.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2767156
  •  go-up   go-down


83. Fujiwara SI, Yamashita Y, Nakamura N, Choi YL, Ueno T, Watanabe H, Kurashina K, Soda M, Enomoto M, Hatanaka H, Takada S, Abe M, Ozawa K, Mano H: High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays. Leukemia; 2008 Oct;22(10):1891-8
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays.
  • Angioimmunoblastic T-cell lymphoma (AILT) and peripheral T-cell lymphoma, unspecified (PTCL-u) are relatively frequent subtypes of T- or natural killer cell lymphoma.
  • To characterize the structural anomalies of chromosomes associated with these disorders, we here determined chromosome copy number alterations (CNAs) and loss of heterozygosity (LOH) at >55,000 single nucleotide polymorphism loci for clinical specimens of AILT (n=40) or PTCL-u (n=33).
  • AILT- or PTCL-u-specific CNAs or LOH were also identified at 21 regions, some spanning only a few hundred base pairs.
  • Our data indicate that AILT and PTCL-u consist of heterogeneous subgroups with distinct transforming genetic alterations.
  • [MeSH-major] Chromosome Aberrations. Loss of Heterozygosity. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Oligonucleotide Array Sequence Analysis. Polymorphism, Single Nucleotide

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633432.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CARD Signaling Adaptor Proteins; 0 / DNA-Binding Proteins; 0 / IKZF2 protein, human; 0 / MYCBP protein, human; 0 / Transcription Factors; 148971-36-2 / Ikaros Transcription Factor; EC 3.4.24.11 / Neprilysin; EC 4.6.1.2 / CARD11 protein, human; EC 4.6.1.2 / Guanylate Cyclase
  •  go-up   go-down


84. Lin HN, Liu CY, Hong YC, Pai JT, Yang CF, Yu YB, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Tzeng CH, Chen PM: Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience. Leuk Lymphoma; 2010 Dec;51(12):2208-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that carries a poor prognosis.
  • Among all patients, 67.7% were Ann Arbor stage III or IV, 58.1% presented with B symptoms, 48.4% had hypoalbuminenia (<35 g/L), and 63.3% had elevated lactate dehydrogenase (LDH) at diagnosis.
  • Despite the prognosis being generally poor, patients with AITL should be treated with the goal of achieving CR, regardless of anthracycline- or non-anthracycline-based chemotherapy.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2011 Jan;52(1):1-2 [21133725.001]
  • (PMID = 21054150.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Thorns C, Bastian B, Pinkel D, Roydasgupta R, Fridlyand J, Merz H, Krokowski M, Bernd HW, Feller AC: Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach. Genes Chromosomes Cancer; 2007 Jan;46(1):37-44
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach.
  • Angioimmunoblastic T-cell lymphoma (AILT) is a histopathologically well-defined entity.
  • However, despite a number of cytogenetic studies, the genetic basis of this lymphoma entity is not clear.
  • Moreover, there is an overlap to some cases of peripheral T-cell lymphoma unspecified (PTCL-u) in respect to morphological and genetic features.
  • We used array-based comparative genomic hybridization (CGH) to study genetic imbalances in 39 AILT and 20 PTCL-u.
  • Array-based CGH revealed complex genetic imbalances in both AILT and PTCL-u.
  • Chromosomal imbalances were more frequent in PTCL-u than in AILT and gains exceeded the losses.
  • The most recurrent changes in AILT were gains of 22q, 19, and 11p11-q14 (11q13) and losses of 13q.
  • Interestingly, gains of 4q (4q28-q31 and 4q34-qtel), 8q24, and 17 were significantly more frequent in PTCL-u than in AILT.
  • Moreover, we could identify a recurrent gain of 11q13 in both AILT and PTCL-u, which has previously not been described in AILT.
  • Trisomies 3 and 5, which have been described as typical aberrations in AILT, were identified only in a small number of cases.
  • In conclusion, CGH revealed common genetic events in peripheral T-cell lymphomas as well as peculiar differences between AILT and PTCL-u.
  • [MeSH-major] Chromosome Aberrations. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17044049.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Yuan CM, Vergilio JA, Zhao XF, Smith TK, Harris NL, Bagg A: CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. Hum Pathol; 2005 Jul;36(7):784-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry.
  • Angioimmunoblastic T-cell lymphoma (AITCL) is a histologically distinct and relatively common subtype of T-cell lymphoma.
  • Although the putative normal cell counterpart is a mature CD4+ T cell, the precise cell of origin remains elusive.
  • We evaluated cases with a diagnosis of AITCL to determine the specificity and utility of CD10 coexpression, particularly by flow cytometry (FCM), in facilitating this diagnosis.
  • Four cases of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), were also analyzed.
  • The lymphoma cells in all 8 AITCL cases were CD4+, CD45RO+ T cells, with classic extrafollicular meshworks of CD21/CD23/CD35+ follicular dendritic cells.
  • CD10 coexpression was not observed in all 4 PTCL-NOS cases.
  • Although not specific for AITCL, increased numbers of BCL6+ cells were seen in AITCL as compared with PTCL-NOS.
  • The finding suggests that AITCL may be a neoplasm of (possibly intrafollicular) CD10+, BCL6+, and CD4+ memory T cells.
  • Although our series is small, our results suggest that CD10 coexpression may be a useful discriminant, particularly if the differential diagnosis is PTCL-NOS, and demonstrate that this can be determined by FCM.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Flow Cytometry. Immunoblastic Lymphadenopathy / metabolism. Lymphoma, T-Cell / metabolism. Neprilysin / metabolism. T-Lymphocytes / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Antigens, CD45 / metabolism. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. Cell Count. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Lymphoma, T-Cell, Peripheral / metabolism. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084948.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Transcription Factors; EC 3.1.3.48 / Antigens, CD45; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


87. Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, Leon A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, García JC, Fernández P, Cañigral G, Bergua J, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea: Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol; 2007 Apr;78(4):290-6
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
  • OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment.
  • Here, we report our experiences with 19 patients treated with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) within the GELTAMO co-operative group between 1992 and 2004.
  • Most patients received peripheral stem cells (90%) coupled with BEAM or BEAC as conditioning regimen (79%).
  • After a median follow-up of 25 months, eight patients died (seven of progressive disease and secondary neoplasia), while actuarial overall survival and progression-free survival at 3 yr was 60% and 55%.
  • Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL.
  • CONCLUSIONS: More than half of the patients with AIL that display unfavourable prognostic factors at diagnosis or relapse would be expected to be alive and disease-free after 3 yr when treated with HDC/ASCT.
  • Patients who are transplanted in a refractory disease state do not benefit from this procedure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Registries. Severity of Illness Index. Spain. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378891.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


88. Hatanaka K, Nakamura N, Kojima M, Ando K, Irie S, Bunno M, Nakamine H, Uekusa T: Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma. Pathol Res Pract; 2010 Jan 15;206(1):9-13
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma.
  • Patients affected by autoimmune diseases (rheumatoid arthritis (RA), psoriasis, and dermatomyositis) treated with methotrexate (MTX) develop lymphoproliferative disorders (LPDs).
  • These cases have been reported to be diffuse large B-cell lymphoma, Hodgkin lymphoma, or polymorphous post-transplant LPDs.
  • However, angioimmunoblastic T-cell lymphoma (AITL) is extremely rare in the medical literature.
  • The affected lymph nodes showed the histological finding of AITL: polymorphous infiltrates, mainly T-cells and arborizing high endothelial venules.
  • [MeSH-major] Arthritis, Rheumatoid / drug therapy. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell / diagnosis. Lymphoproliferative Disorders / chemically induced. Lymphoproliferative Disorders / diagnosis. Methotrexate / adverse effects
  • [MeSH-minor] Aged. Antirheumatic Agents / adverse effects. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cell Proliferation. Diagnosis, Differential. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / immunology. Female. Herpesvirus 4, Human / immunology. Humans. Male

  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19628340.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antirheumatic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


89. Viallard JF, Lazaro E, Lafon ME, Pellegrin JL: Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma. Leuk Lymphoma; 2005 Nov;46(11):1659-62
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma.
  • Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating infectious disease, caused by the human polyomavirus JC (JCV), that usually occurs in immunocompromised patients.
  • In this setting, PML has been observed in increasing numbers of patients with hematological malignancies, mostly lymphoproliferative B-cell disorders.
  • We report the successful use of cidofovir in a patient who developed PML 6 months before angioimmunoblastic T-cell lymphoma (AITL) was diagnosed.
  • Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating infectious disease, caused by the human polyomavirus JC (JCV), that usually occurs in immunocompromised patients.
  • In this setting, PML has been observed in increasing numbers of patients with hematological malignancies, mostly lymphoproliferative B-cell disorders.
  • We report the successful use of cidofovir in a patient who developed PML 6 months before angioimmunoblastic T-cell lymphoma (AITL) was diagnosed.
  • [MeSH-major] Cytosine / analogs & derivatives. Immunoblastic Lymphadenopathy / complications. Leukoencephalopathy, Progressive Multifocal / drug therapy. Lymphoma, T-Cell / complications. Organophosphonates / therapeutic use
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nerve Fibers, Myelinated / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334909.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


90. Reichard KK, Schwartz EJ, Higgins JP, Narasimhan B, Warnke RA, Natkunam Y: CD10 expression in peripheral T-cell lymphomas complicated by a proliferation of large B-cells. Mod Pathol; 2006 Mar;19(3):337-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression in peripheral T-cell lymphomas complicated by a proliferation of large B-cells.
  • CD10 expression by the neoplastic T cells in angioimmunoblastic T-cell lymphoma was recently described.
  • As cases of peripheral T-cell lymphoma, unspecified, fail to show similar CD10 expression, this feature helps discriminate between these two entities, particularly in cases exhibiting morphologic overlap.
  • Given these findings, we studied CD10 expression in a subtype of peripheral T-cell lymphoma known as peripheral T-cell lymphoma complicated by a proliferation of large B cells and compared it with angioimmunoblastic T-cell lymphoma and angioimmunoblastic T-cell lymphoma with a large B-cell proliferation.
  • A total of 33 cases were identified including peripheral T-cell lymphoma complicated by a proliferation of large B cells (10), angioimmunoblastic T-cell lymphoma (10) and angioimmunoblastic T-cell lymphoma with a large B-cell proliferation (13).
  • Diagnoses were established by hematoxylin and eosin (H&E) stain, immunohistochemistry and/or molecular findings (polymerase chain reaction for T-cell receptor-gamma gene rearrangement).
  • Two of 10 cases of peripheral T-cell lymphoma complicated by a proliferation of large B cells showed aberrant CD10 expression (20%) compared to 9/10 cases of angioimmunoblastic T-cell lymphoma (90%) and 8/13 of angioimmunoblastic T-cell lymphoma with a large B-cell proliferation (62%).
  • One case each of angioimmunoblastic T-cell lymphoma and angioimmunoblastic T-cell lymphoma with a large B-cell proliferation showed a rare, but not unequivocal, CD10+ atypical cell.
  • Four cases of angioimmunoblastic T-cell lymphoma with a large B-cell proliferation were CD10 negative.
  • Of the 2 CD10+ peripheral T-cell lymphoma complicated by a proliferation of large B cells, one had no H&E or IHC features of angioimmunoblastic T-cell lymphoma and showed only a rare positive cell.
  • The second case, a lung biopsy, exhibited diffuse CD10 tumor cell positivity.
  • Our data indicate that only 20% of cases of peripheral T-cell lymphoma complicated by a proliferation of large B cells show CD10 expression by the neoplastic T cells in contrast to angioimmunoblastic T-cell lymphoma and angioimmunoblastic T-cell lymphoma with a large B-cell proliferation which exhibit CD10 staining in 90 and 62% of cases, respectively.
  • This finding does not reach statistical significance with a P-value of 0.57 (Fisher's exact test).
  • [MeSH-major] B-Lymphocytes / pathology. Cell Proliferation. Lymphoma, T-Cell, Peripheral / pathology. Neprilysin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Diagnosis, Differential. Female. Herpesvirus 4, Human / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. RNA, Viral / genetics. RNA, Viral / metabolism. Receptors, Complement 3d / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400325.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 34233
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / RNA, Viral; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


91. Decouvelaere AV, Morschhauser F, Buob D, Copin MC, Dumontet C: Heterogeneity of protein kinase C beta(2) expression in lymphoid malignancies. Histopathology; 2007 Apr;50(5):561-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Protein kinase C (PKC) beta is an important regulator of lymphoid survival and its expression has been shown to be altered in lymphomas.
  • The aim was to determine the expression of PKC beta(2) in various subtypes of lymphoproliferative diseases by immunohistochemistry.
  • METHODS AND RESULTS: One hundred and forty archival samples representing various subtypes of lymphoproliferative diseases were analysed.
  • Certain subtypes, such as mantle cell, lymphocytic or follicular lymphoma, were found to express PKC beta(2) in > 90% of the samples.
  • In follicular lymphomas, the follicular lymphomatous areas were constantly labelled, whereas residual germinal centres remained negative.
  • Most angioimmunoblastic T-cell lymphomas, lymphoblastic T-cell lymphomas and marginal zone/mucosa-associated lymphoid tissue (MALT) lymphomas were labelled with anti-PKC betaII antibody, but the pattern of expression was more heterogeneous in these subtypes.
  • A minority of diffuse large B-cell lymphomas were stained and most plasma cell malignancies were negative.
  • None of the cases of Hodgkin's disease and anaplastic large cell lymphoma expressed PKC beta(2).
  • CONCLUSIONS: PKC beta(2) expression varies significantly among lymphoproliferative diseases.
  • In our series, the highest level of expression was found in mantle cell lymphomas and chronic lymphocytic lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17394491.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta
  •  go-up   go-down


92. Mizobe T, Tsukada J, Higashi T, Iwashige A, Ota T, Kawano I, Kubota A, Matsuura A, Morimoto H, Ogawa R, Toda Y, Tanaka Y: [Angioimmunoblastic T-cell lymphoma accompanied by pure red cell aplasia]. Rinsho Ketsueki; 2005 Mar;46(3):211-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma accompanied by pure red cell aplasia].
  • A 71-year-old woman was admitted in December 2002 because of lymphadenopathy, hepatosplenomegaly and pleural effusion.
  • Bone marrow aspiration showed an almost total absence of erythroblasts and no pathological cell proliferation.
  • The diagnosis of angioimmunoblastic T-cell lymphoma (AILT) was made based on the lymph node histological findings.
  • After combination chemotherapy (THP-COP), remission was achieved in both the pure red cell aplasia (PRCA) and AILT.
  • Remission was also accompanied by normalization of the Coombs tests, suggesting that autoimmune mechanisms in AILT may contribute to the development of PRCA.
  • [MeSH-major] Immunoblastic Lymphadenopathy / complications. Red-Cell Aplasia, Pure / etiology

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447717.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  • [Number-of-references] 10
  •  go-up   go-down


93. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ: Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol; 2006 Jul;30(7):802-10
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma.
  • In a study of a wide range of lymphoproliferative disorders, neoplastic T cells in 23 cases of angioimmunoblastic lymphoma were immunoreactive for PD-1, but other subtypes of T cell and B cell non-Hodgkin lymphoma, as well as classic Hodgkin lymphoma, did not express PD-1.
  • The pattern of PD-1 immunostaining of neoplastic cells in angioimmunoblastic lymphoma was similar to that reported for CD10, a recently described marker of neoplastic T cells in angioimmunoblastic lymphoma.
  • Tumor-associated follicular dendritic cells in cases of angioimmunoblastic lymphoma were found to express PD-L1, the PD-1 ligand.
  • In addition, PD-1-positive reactive T cells formed rosettes around neoplastic L&H cells in 14 cases of nodular lymphocyte predominant Hodgkin lymphoma studied.
  • These findings, along with data from previous studies, suggest that angioimmunoblastic lymphoma is a neoplasm of germinal center-associated T cells and that there is an association of germinal center-associated T cells and neoplastic cells in nodular lymphocyte predominant Hodgkin lymphoma.
  • PD-1 is a useful new marker for angioimmunoblastic lymphoma and lends further support to a model of T-cell lymphomagenesis in which specific subtypes of T cells may undergo neoplastic transformation and result in specific, distinct histologic, immunophenotypic, and clinical subtypes of T-cell neoplasia.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Immunol. 2002 Feb;2(2):116-26 [11910893.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9337-42 [9256483.001]
  • [Cites] J Immunol. 2003 Feb 1;170(3):1257-66 [12538684.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):861-71 [12598320.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1539-44 [12707037.001]
  • [Cites] Am J Clin Pathol. 2003 Dec;120(6):866-73 [14671975.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):292-7 [15323146.001]
  • [Cites] N Engl J Med. 1997 Aug 14;337(7):453-8 [9250847.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):956-64 [9706975.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):403-11 [10208461.001]
  • [Cites] Blood. 1999 May 15;93(10):3487-93 [10233901.001]
  • [Cites] Blood. 2005 Jan 1;105(1):13-21 [15353480.001]
  • [Cites] Nat Immunol. 2005 Mar;6(3):280-6 [15685176.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] J Exp Med. 2001 Jun 18;193(12):1373-81 [11413192.001]
  • [Cites] Blood. 2000 Jul 15;96(2):685-90 [10887135.001]
  • [Cites] Immunol Lett. 2002 Oct 1;83(3):215-20 [12095712.001]
  • (PMID = 16819321.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / P01 AI056299-01; United States / NIAID NIH HHS / AI / AI056299-01; United States / NIAID NIH HHS / AI / AI056299-02; United States / NIAID NIH HHS / AI / P01 AI056299; United States / NIAID NIH HHS / AI / P01 AI056299-02; United States / NIAID NIH HHS / AI / AI 39671; United States / NIAID NIH HHS / AI / AI039671-04; United States / NIAID NIH HHS / AI / AI 56299; United States / NIAID NIH HHS / AI / AI056299-03; United States / NIAID NIH HHS / AI / P01 AI039671; United States / NIAID NIH HHS / AI / P01 AI039671-04; United States / NIAID NIH HHS / AI / P01 AI056299-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  • [Other-IDs] NLM/ NIHMS298194; NLM/ PMC3137919
  •  go-up   go-down


94. Zhou Y, Attygalle AD, Chuang SS, Diss T, Ye H, Liu H, Hamoudi RA, Munson P, Bacon CM, Dogan A, Du MQ: Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol; 2007 Jul;138(1):44-53
MedlinePlus Health Information. consumer health - Infectious Mononucleosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load.
  • The clinical and histological presentations of angioimmunoblastic T-cell lymphoma (AITL) often mimic an infectious process.
  • High EBV load was also significantly associated with B-cell monoclonality.
  • Our results demonstrate an association between EBV and HHV6B infection and the histological progression of AITL, suggesting that these viruses may play a role in the pathogenesis of this lymphoma.
  • [MeSH-major] Herpesvirus 4, Human / pathogenicity. Herpesvirus 6, Human / pathogenicity. Infectious Mononucleosis / complications. Lymphoma, Large-Cell, Immunoblastic / virology. Roseolovirus Infections / complications. Tumor Virus Infections / complications
  • [MeSH-minor] Antigens, CD20 / analysis. Antigens, CD79 / analysis. Chi-Square Distribution. Disease Progression. Genes, Viral. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization. Neprilysin / analysis. Polymerase Chain Reaction / methods. Viral Load

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555446.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD79; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


95. Carbone A, Gloghini A, Dotti G: EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist; 2008 May;13(5):577-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since its discovery as the first human tumor virus, Epstein-Barr virus (EBV) has been implicated in the development of a wide range of B-cell lymphoproliferative disorders, including Burkitt's lymphoma, classic Hodgkin's lymphoma, and lymphomas arising in immunocompromised individuals (post-transplant and HIV-associated lymphoproliferative disorders).
  • T-cell lymphoproliferative disorders that have been reported to be EBV associated include a subset of peripheral T-cell lymphomas, angioimmunoblastic T-cell lymphoma, extranodal nasal type natural killer/T-cell lymphoma, and other rare histotypes.
  • The focus of this review is on the pathology, diagnosis, classification, and pathogenesis of EBV-associated lymphomas.
  • Recent advances in EBV cell-based immunotherapy, which is beginning to show promise in the treatment of EBV-related disorders, are discussed.
  • [MeSH-major] Epstein-Barr Virus Infections / classification. Herpesvirus 4, Human / genetics. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / virology
  • [MeSH-minor] Adult. Disease Susceptibility. Humans. Immunocompromised Host / immunology. Immunotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18515742.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


96. Bonzheim I, Geissinger E, Tinguely M, Roth S, Grieb T, Reimer P, Wilhelm M, Rosenwald A, Müller-Hermelink HK, Rüdiger T: Evaluation of FoxP3 expression in peripheral T-cell lymphoma. Am J Clin Pathol; 2008 Oct;130(4):613-9
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of FoxP3 expression in peripheral T-cell lymphoma.
  • Peripheral T-cell lymphomas (PTCLs) are biologically heterogeneous and have not been successfully correlated with specific T-cell subsets.
  • We investigated PTCL, not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AILT), and anaplastic large cell lymphoma (ALCL) cases for FoxP3 expression to determine a potential derivation from regulatory T (Treg) cells.
  • One PTCL-NOS case strongly expressed FoxP3 in the neoplastic T cells and showed unusual histomorphologic features with a dense infiltration of the lymph node by immunoblastic T cells and almost no reactive background infiltrate.
  • The patient died shortly after diagnosis, suggesting that biologic properties of Treg cells may have contributed to the rapidly fatal clinical course.
  • All remaining PTCL-NOS and AILT cases showed FoxP3 positivity only in the reactive infiltrate.
  • FoxP3+ PTCL-NOS presumably derived from bona fide Treg cells occurs but seems rare in the Western population.
  • [MeSH-major] Forkhead Transcription Factors / biosynthesis. Lymphoma, T-Cell, Peripheral / immunology. Lymphoma, T-Cell, Peripheral / metabolism. T-Lymphocyte Subsets / metabolism. T-Lymphocytes, Regulatory / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794055.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


97. Balagué O, Martínez A, Colomo L, Roselló E, Garcia A, Martínez-Bernal M, Palacín A, Fu K, Weisenburger D, Colomer D, Burke JS, Warnke RA, Campo E: Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features. Am J Surg Pathol; 2007 Sep;31(9):1310-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features.
  • Clonal B-cell populations have been described in peripheral T-cell lymphomas (PTCL) as secondary Epstein-Barr virus (EBV) driven B-cell expansions that may evolve to an overt B-cell lymphoma.
  • EBV-negative B-cell proliferations associated with T-cell lymphomas are uncommon and not well characterized.
  • We studied 15 patients who developed an EBV-negative B-cell proliferation or malignant lymphoma associated with PTCL.
  • The T-cell tumors were 8 PTCL, not otherwise specified, 4 angioimmunoblastic T-cell lymphomas, and 3 cutaneous PTCL.
  • The B-cell component was intermingled with the PTCL in all patients and it was classified as clonal/monotypic plasma cell proliferation in 8 lesions, clonal/monotypic large B-cell proliferation in 4 patients, and B-cell lymphoma with plasmacytic/plasmablastic differentiation in 3 patients.
  • Two patients had 2 clonally unrelated plasma cell proliferations associated with the same PTCL.
  • Clonal IgH and T-cell receptor rearrangements were detected in 11/12 and 11/13 cases examined, respectively.
  • Sequential samples in 7 patients showed persistence of the PTCL and the B-cell component in 4, the PTCL without the B-cell lymphoma in 2, and progression of the B-cell neoplasm in 1.
  • In conclusion, EBV-negative clonal or mononotypic B-cell proliferations in patients with PTCL present with a spectrum of lesions ranging from plasma cell proliferations to overt lymphomas with plasmacytic/plasmablastic features.
  • [MeSH-major] Cell Proliferation. Herpesvirus 4, Human. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell, Peripheral / pathology. Plasma Cells / pathology
  • [MeSH-minor] Adolescent. Aged. Aged, 80 and over. Cell Differentiation. Clone Cells / pathology. Clone Cells / virology. Cytomegalovirus. Female. Gene Expression Regulation, Neoplastic. Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Herpesvirus 8, Human. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721185.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, Komatani H, Sugita Y, Ohshima K: Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int; 2008 Feb;58(2):89-97

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases.
  • Although various CD markers have been analyzed in T-cell and natural killer (NK)-cell lymphomas, the sensitivity and specificity of these phenotypic features have not been satisfactorily characterized.
  • Flow cytometry (FCM) was used to determine the phenotypic pattern of 490 T/NK-cell lymphomas with the aid of a set of surface antigens (CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD25, CD30, CD34, and CD56).
  • In data obtained from 319 patients, CD10 expression was detected in 57% of angioimmunoblastic T-cell lymphomas, CD30 in 93% of anaplastic large cell lymphomas, CD34 in 50% of lymphoblastic lymphomas, and CD56 in 100% of extranodal NK/T-cell lymphomas nasal type.
  • A total of 92% of adult T-cell leukemia/lymphomas (ATLL) had expression of CD25 and downregulation of CD7.
  • Of special interest is that 92 ATLL (50%) were CD4+CD7-CD25+ phenotype while only four peripheral T-cell lymphoma unspecified (9%) and one (9%) cutaneous T-cell lymphoma had this phenotype.
  • Phenotypic analysis using FCM was thus found to be useful for differential diagnosis of T-cell and NK-cell lymphomas.
  • [MeSH-major] Flow Cytometry / methods. Killer Cells, Natural / pathology. Lymphoma, T-Cell / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Antigens, CD / analysis. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunophenotyping. Lymph Nodes / immunology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199158.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Tzankov AS, Went PT, Münst S, Papadopoulos T, Jundt G, Dirnhofer SR: Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. Mod Pathol; 2007 Jun;20(6):632-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare expression of BSAP (PAX-5) in mature T-cell lymphomas.
  • Lineage determination in lymphomas is based on the assessment of lineage-specific markers, such as the B-cell-specific activator protein of the paired box family (BSAP, PAX-5) for the B-cell lineage.
  • BSAP is thought to be expressed exclusively in B cells from the pro-B- to the mature B-cell stage and then silenced in plasma cells.
  • BSAP has oncogenic potential and experimental evidence shows that the T-cell lineage is prone to this effect.
  • Herein, we report on a BSAP-positive peripheral T-cell lymphoma with monoclonal T-cell receptor gamma-gene rearrangement.
  • To assess the relative frequency of BSAP expression in mature T-cell lymphomas, we constructed and examined a tissue microarray consisting of 43 angioimmunoblastic T-cell lymphomas and peripheral T-cell lymphomas and detected no additional BSAP-positive cases.
  • To conclude, BSAP can probably contribute to T-cell lymphomagenesis not only in vitro, but also in vivo.
  • It is rarely expressed in peripheral T-cell lymphoma, thus its detection on lymphoid malignancies cannot be considered definitively lineage specific.
  • [MeSH-major] B-Cell-Specific Activator Protein / biosynthesis. Lymphoma, T-Cell / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / biosynthesis. Cell Lineage. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Lymphoma, T-Cell, Peripheral / metabolism. Male. Middle Aged. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431414.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / PAX5 protein, human
  •  go-up   go-down


100. Greer JP: Therapy of peripheral T/NK neoplasms. Hematology Am Soc Hematol Educ Program; 2006;:331-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of peripheral T/NK neoplasms.
  • The mature T/natural killer (NK) lymphoma/leukemias represent 5-15% of all non-Hodgkin lymphoma.
  • These diseases have a geographic variation, with more nodal disease in North America and Europe, including peripheral T cell lymphomas, unspecified, anaplastic large cell lymphoma, and angioimmunoblastic T cell lymphoma; and more extranodal disease in Asia due to Epstein-Barr virus-related nasal NK/T lymphoma and human T-cell leukemia virus (HTLV)-1-associated adult T cell leukemia/lymphoma.
  • The prognosis in most peripheral T/NK neoplasms is poor, with 5-year survival less than 30%.
  • Progress has been slow due to the rarity of the diseases, geographic variation, relative chemoresistance, and lack of randomized trials.
  • In this review, topics include the question of CHOP as standard therapy, prognostic factors, disease-adapted therapy, novel approaches, monoclonal antibody therapy, and stem cell transplantation.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124080.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down






Advertisement